[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 146
1. Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, Stetler-Stevenson M: Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am J Clin Pathol; 2010 Apr;133(4):592-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.
  • Little information exists regarding the detection of minimal residual disease (MRD) in adult T-cell leukemia/lymphoma (ATLL).
  • We evaluated 75 peripheral blood samples from 17 ATLL cases using flow cytometry (FC); 50 of the samples were concurrently evaluated by polymerase chain reaction (PCR) for clonal T-cell receptor gamma chain (TRG) gene rearrangement and the presence of human T-cell lymphotropic virus-1 proviral sequences.
  • Residual ATLL cells were identified using a multiparametric approach to identify aberrant T-cell immunophenotypes.
  • In 2 patients, there was complete remission; 4 patients had disease refractory to therapy, and 3 died; 11 others had persistent disease with variable numbers of ATLL cells in the peripheral blood.
  • [MeSH-major] Flow Cytometry. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231613.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


2. Malamut G, El Machhour R, Montcuquet N, Martin-Lannerée S, Dusanter-Fourt I, Verkarre V, Mention JJ, Rahmi G, Kiyono H, Butz EA, Brousse N, Cellier C, Cerf-Bensussan N, Meresse B: IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest; 2010 Jun;120(6):2131-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Enteropathy-associated T cell lymphoma is a severe complication of celiac disease (CD).
  • Here we show that the survival signals delivered by IL-15 to freshly isolated human IELs and to human IEL cell lines derived from CD patients with type II refractory CD (RCDII) - a clinicopathological entity considered an intermediary step between CD and enteropathy-associated T cell lymphoma - depend on the antiapoptotic factors Bcl-2 and/or Bcl-xL.
  • [MeSH-minor] Adult. Cytokines / immunology. Cytokines / metabolism. Cytokines / pharmacology. Enterocytes / immunology. Enterocytes / metabolism. Humans. Intestine, Small / immunology. Intestine, Small / metabolism. Intestines / immunology. Intestines / metabolism. Janus Kinase 3 / immunology. Janus Kinase 3 / metabolism. Leukemia / complications. Leukemia / immunology. Leukemia / metabolism. Phosphorylation. Protein Binding / immunology. STAT3 Transcription Factor / immunology. STAT3 Transcription Factor / metabolism. STAT3 Transcription Factor / pharmacology. Signal Transduction / drug effects. Signal Transduction / immunology


3. Raza S, Naik S, Kancharla VP, Tafera F, Kalavar MR: Dual-Positive (CD4+/CD8+) Acute Adult T-Cell Leukemia/Lymphoma Associated with Complex Karyotype and Refractory Hypercalcemia: Case Report and Literature Review. Case Rep Oncol; 2010 Sep;3(3):489-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual-Positive (CD4+/CD8+) Acute Adult T-Cell Leukemia/Lymphoma Associated with Complex Karyotype and Refractory Hypercalcemia: Case Report and Literature Review.
  • We describe a rare case of adult T-cell leukemia characterized by an expansion of CD4+ CD8+ double-positive lymphocytes associated with human T-lymphotropic virus type 1 (HTLV-1) and a complex karyotype in a 43-year-old Caribbean male who was initially admitted to our hospital with significant lethargy, visual disturbances, dysphagia, right facial palsy and numbness in both feet for 3 days.
  • The polymerase chain reaction analysis showed a distinct band of the T-cell receptor γ gene, revealing T-cell clonal integration of the proviral DNA of HTLV-1, thus confirming the diagnosis of acute adult T-cell leukemia/lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):1-5 [10077143.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):395-400 [7812198.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3612-20 [11369658.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3875-81 [11389029.001]
  • [Cites] J R Soc Med. 2003 Mar;96(3):126-7 [12612113.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):527-31 [14657765.001]
  • [Cites] Leuk Res. 1992;16(5):435-41 [1625468.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):974-83 [16585963.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):875-82 [17951212.001]
  • [Cites] Leuk Res. 1991;15(7):619-25 [1861543.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):745-8 [1911223.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(11):1096-101 [2213510.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Leuk Res. 1985;9(11):1353-9 [2867255.001]
  • [Cites] Leuk Res. 1987;11(7):665-8 [2886703.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9171-5 [3194418.001]
  • [Cites] Int J Hematol. 1997 Oct;66(3):257-78 [9401272.001]
  • [Cites] J Biol Chem. 1993 Jan 15;268(2):1174-9 [8380405.001]
  • [Cites] Int J Dermatol. 2006 Oct;45(10):1193-5 [17040438.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):357-69 [2983135.001]
  • [Cites] Nature. 1988 Oct 13;335(6191):642-4 [3262830.001]
  • [Cites] Leuk Res. 2000 Apr;24(4):353-8 [10713333.001]
  • (PMID = 21611103.001).
  • [ISSN] 1662-6575
  • [Journal-full-title] Case reports in oncology
  • [ISO-abbreviation] Case Rep Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3100272
  • [Keywords] NOTNLM ; Acute T-cell leukemia / Cyclophosphamide / Doxorubicin / Etoposide / Human T-lymphotropic virus type 1 (HTLV-1) / Prednisone / Vincristine
  •  go-up   go-down


Advertisement
4. Brown M, Bellon M, Nicot C: Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood; 2007 Feb 15;109(4):1653-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.
  • Adult T-cell leukemia (ATL) is an aggressive lymphoproliferative disease of poor clinical prognosis associated with infection by the human T-cell leukemia virus type I (HTLV-I).
  • The use of arsenic trioxide (As2O3) has been shown to effectively treat acute promyelocytic leukemia (APL) with greater than 80% of patients achieving complete remission.
  • In this study we report a potent synergistic effect of the combination of arsenic trioxide and interferon alpha (As/IFN-alpha) with emodin and DHA on cell-cycle arrest and cell death of HTLV-I-infected cells.
  • Our data provide a rationale for combined use of As/IFN-alpha with emodin and DHA in patients with ATL refractory to conventional therapy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. EMODIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1996 Jul 4;13(1):135-42 [8700539.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6 [8680890.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Virology. 1997 Sep 15;236(1):47-53 [9299616.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26079-82 [9334169.001]
  • [Cites] Br J Haematol. 1998 Dec;103(3):721-8 [9858223.001]
  • [Cites] Blood. 1999 Jan 1;93(1):278-83 [9864171.001]
  • [Cites] Int J Hematol. 1999 Apr;69(3):203-5 [10222661.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):347-55 [15621824.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):525-40 [15580311.001]
  • [Cites] Oncogene. 2005 May 5;24(20):3339-47 [15735709.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6719-28 [16007163.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):765-72 [16106398.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):313-21 [16157375.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2090-7 [16786598.001]
  • [Cites] Leuk Res. 2000 Apr;24(4):299-305 [10713327.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):290-3 [10846838.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2849-55 [11023521.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1603-6 [11080798.001]
  • [Cites] EMBO Rep. 2001 Feb;2(2):96-101 [11258719.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Apr 20;282(5):1110-3 [11302729.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2514-26 [11420661.001]
  • [Cites] Leuk Lymphoma. 2001 Jan;40(3-4):287-94 [11426550.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1150-9 [11493464.001]
  • [Cites] Virus Res. 2001 Oct 30;78(1-2):79-92 [11520582.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3762-9 [11739184.001]
  • [Cites] Apoptosis. 2002 Jun;7(3):209-15 [11997664.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] Blood. 2002 Dec 1;100(12):4129-38 [12393612.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2275-9 [12613513.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4576-82 [12560223.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4990-7 [12609832.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):108-16 [14729614.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6753-60 [14625274.001]
  • [Cites] FEBS Lett. 2004 Mar 26;562(1-3):165-70 [15044019.001]
  • [Cites] Hematol J. 2004;5(2):130-4 [15048063.001]
  • [Cites] Biochem Pharmacol. 2004 Jul 15;68(2):361-71 [15194008.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):707-12 [15382055.001]
  • [Cites] Blood. 1988 Nov;72(5):1805-16 [2846094.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2217-21 [8384067.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):771-4 [7917938.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] N Engl J Med. 1995 Nov 9;333(19):1285-6 [7566010.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):713-5 [8826899.001]
  • (PMID = 17077332.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016443; United States / NCI NIH HHS / CA / R01 CA106258; United States / NCRR NIH HHS / RR / PZ0 RR016443; United States / NCI NIH HHS / CA / R01CA106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Interferon-alpha; 0 / Oxides; 0 / Reactive Oxygen Species; 0 / Transcription Factor AP-1; 25167-62-8 / Docosahexaenoic Acids; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; KA46RNI6HN / Emodin; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC1794054
  •  go-up   go-down


5. Fett NM, Siddiqui J, Creswell CH, Zhang D, Lloyd R, Wood GS: Adult T-cell leukemia/lymphoma in a patient from Romania: a case report and review of the literature. J Cutan Pathol; 2008 Oct;35 Suppl 1:32-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma in a patient from Romania: a case report and review of the literature.
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare malignancy caused by human T-cell leukemia virus-1.
  • Narrow-band ultraviolet-B (UV-B) therapy and mid-potency topical steroids resulted in skin clearing for approximately 5 months after diagnosis; however, she subsequently relapsed with disease refractory to both narrow band UV-B and psoralen plus ultraviolet A (PUV-A), progressed to acute ATLL and expired secondary to complications.
  • [MeSH-major] HTLV-I Infections / complications. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / physiopathology. Ultraviolet Therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Female. Flow Cytometry. Humans. Immunohistochemistry. Polymerase Chain Reaction. Respiratory Tract Infections / pathology. Romania. Vitiligo / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544058.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


6. Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P: Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol; 2006 Apr 20;24(12):1917-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
  • PURPOSE: To evaluate the efficacy and safety of clofarabine, a novel deoxyadenosine analog, in pediatric patients with refractory or relapsed acute lymphoblastic leukemia (ALL).
  • PATIENTS AND METHODS: In a phase II, open-label, multicenter study, 61 pediatric patients with refractory or relapsed ALL received clofarabine 52 mg/m2 intravenously over 2 hours daily for 5 days, every 2 to 6 weeks.
  • Remissions were durable enough to allow patients to proceed to hematopoietic stem-cell transplantation (HSCT) after clofarabine.
  • CONCLUSION: Clofarabine is active as a single agent in pediatric patients with multiple relapsed or refractory ALL.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adenine Nucleotides. Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Infusions, Intravenous. Male. Recurrence. Treatment Outcome


7. Wang HX, Yan HM, Liu J, Duan LN, Wang ZD, Zhu L, Xue M, Guo ZK: Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. Leuk Lymphoma; 2009 Sep;50(9):1488-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement.
  • Here, we report the preliminary results of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) with granulocyte-colony-stimulating factor (G-CSF) mobilized bone marrow grafts without T-cell depletion for 10 patients with refractory non-Hodgkin lymphoma accompanied by bone marrow involvement.
  • The results here suggest that haplo-HSCT might provide an opportunity of myeloablative therapy for refractory lymphoma with marrow infiltration.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Bone Marrow Neoplasms / therapy. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Child. Drug Resistance, Neoplasm. Female. Graft vs Host Disease. Granulocyte Colony-Stimulating Factor / therapeutic use. Haplotypes. Hematopoietic Stem Cell Mobilization / methods. Histocompatibility Testing. Humans. Male. Pilot Projects. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811326.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


8. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA: Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol; 2006 May 01;24(13):2105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
  • Twenty-four patients had mantle cell lymphoma (MCL), 13 had follicular lymphoma (FL), six had lymphoplasmacytic lymphoma, six had Hodgkin's disease (HD), and one each had diffuse large B-cell lymphoma and adult T-cell leukemia/lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma / drug therapy. Pyrazines / therapeutic use. Tumor Necrosis Factor-alpha / analysis
  • [MeSH-minor] Adult. Aged. Bortezomib. Cell Line, Tumor. Cell Survival / drug effects. Cytokines / blood. Doxorubicin / pharmacology. Female. Humans. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Cytokines; 0 / Pyrazines; 0 / Tumor Necrosis Factor-alpha; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin
  •  go-up   go-down


9. Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP: Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk; 2010 Jun;10(3):192-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
  • BACKGROUND: Patients with diffuse large B-cell lymphoma (DLBCL) who are not cured by initial therapy sometimes experience disease-free survival after autologous stem cell transplantation.
  • PATIENTS AND METHODS: We identified patients with relapsed or refractory DLBCL at Weill Cornell Medical Center for whom data on responses to second-line chemotherapy were available.
  • RESULTS: A total of 74 patients with relapsed or refractory DLBCL who underwent second-line chemotherapy between 1996 and 2007 were identified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Stem Cell Transplantation. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20511164.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ahmed T, Rashid K, Waheed F, Kancherla R, Qureshi Z, Hoang A, Richter J, Ali MF, Goldberg R, Liu D, Seiter K: Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant. Leuk Lymphoma; 2005 Mar;46(3):405-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant.
  • Dose-intensive chemotherapy with autologous stem cell support is commonly used in resistant/refractory cases of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
  • We used non cross-resistant conditioning regimens with thiotepa, mitoxantrone and carboplatin (TMJ) followed by ifosphamide, carboplatin and etoposide (ICE) with autologous stem cell rescue in an attempt to maximize dose intensity and achieve long-term remission.
  • Twenty-nine patients with HD and 47 with NHL underwent autologous stem cell transplant using TMJ as the conditioning regimen for the first transplant.
  • On an intent to treat basis, 32.14% of patients with HD refractory to initial or subsequent therapy survived long term as opposed to 12.76% of patients with NHL.
  • Dose-intensive chemotherapy with tandem transplantation is an option in patients with resistant/refractory lymphoma who have very limited treatment options and poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Salvage Therapy / methods. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621831.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS: Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma; 2009 Jul;50(7):1096-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
  • Twenty-three patients with relapsed or refractory myeloma or other plasma cell cancers were treated with the VDT regimen.
  • Patient had a median of five prior therapies and 65.2% were refractory to their last regimen.
  • We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma.
  • [MeSH-minor] Adult. Aged. Bortezomib. Female. Humans. Male. Middle Aged. Remission Induction. Salvage Therapy / methods. Steroids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479618.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 0 / Steroids; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin
  •  go-up   go-down


12. Manoukian G, Hagemeister F: Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther; 2009 Nov;9(11):1445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 1999, the FDA approved the use of denileukin diftitox for patients with persistent or relapsed CD25-positive cutaneous T-cell lymphoma (CTCL), but Ontak has been reported to be an effective therapy for other neoplastic and non-neoplastic conditions.
  • Oncological uses include therapy for CD25-negative T-cell lymphoma, recurrent and refractory chronic lymphocytic leukemia (CLL), non-Hodgkin's B-cell lymphoma (NHL), and human T-cell lymphotropic virus- 1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817678.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  • [Number-of-references] 37
  •  go-up   go-down


13. Korycka A, Lech-Marańda E, Robak T: Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov; 2008 Jun;3(2):123-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, all these drugs have demonstrated promising activity in patients with relapsed and refractory acute lymphoblastic leukemia (ALL).
  • CAFdA was approved for the therapy of relapsed or refractory ALL in the third line of treatment.
  • It has proved promising in pediatric patients as well as in some patients who are able to proceed to allogenic hematopietic stem cell transplantation (HSCT).
  • Moreover, the drug exhibits an efficacy in acute myeloid leukemia (AML), blast crisis of chronic myelogenous leukemia (CML-BP) and myelodysplastic syndrome (MDS).
  • Nelarabine is recommended for T-ALL and T-cell lymphoblastic lymphoma (T-LBL) with the overall response rates ranging from 11 to 60%.
  • Forodesine is a purine nucleoside phosphorylase (PNP) inhibitor and it has shown activity in relapsed and refractory T- and B-cells leukemias as well as in cutaneous T-cell lymphoma (CTCL).
  • Great hopes are currently set on the use of these drugs in the treatment of lymphoid and myeloid malignancies in adult and in pediatric patients, however ongoing studies will help to define their role in the standard therapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537755.001).
  • [ISSN] 1574-8928
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; 60158CV180 / nelarabine; 762RDY0Y2H / clofarabine
  • [Number-of-references] 102
  •  go-up   go-down


14. Dubowy R, Graham M, Hakami N, Kletzel M, Mahoney D, Newman E, Ravindranath Y, Camitta B: Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. J Pediatr Hematol Oncol; 2008 May;30(5):353-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.
  • At concentrations >0.1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro.
  • This study of children with refractory acute leukemia was designed to take advantage of this biochemical modulation.
  • Thirty-three children [26 acute lymphocytic leukemia (ALL), 7 acute nonlymphocytic leukemia] were treated; 29 received at least 1 full course.
  • This combination of HU and ara-C is tolerable and has efficacy in refractory leukemias.
  • [MeSH-major] Cytarabine / toxicity. Hydroxyurea / toxicity. Leukemia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Infection / epidemiology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality. Liver / drug effects. Liver / pathology. Skin / drug effects. Skin / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458568.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ NIHMS721202; NLM/ PMC4601800
  •  go-up   go-down


15. Sinha-Datta U, Taylor JM, Brown M, Nicot C: Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis; 2008 Jan;13(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult T-cell leukemia/lymphoma (ATLL) is an aggressive lymphoproliferative disease of very poor clinical prognosis associated with infection by the human T-cell leukemia virus type I (HTLV-I).
  • Treatment of patients with ATLL using conventional chemotherapy has limited benefit because HTLV-I cells are refractory to most apoptosis-inducing agents.
  • In this study, we report that Celecoxib induces cell death via the intrinsic mitochondrial pathway in HTLV-I transformed leukemia cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952603.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106258; United States / NCI NIH HHS / CA / R01 CA115398; United States / NCI NIH HHS / CA / CA 106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Cyclooxygenase Inhibitors; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazoles; 0 / Sulfonamides; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


16. Otero L, Camargo A, Figueiras Junior RD, Dobbin J, Campos MM, Abdelhay E, Fernandez Tde S: The rare t(5;11) with a new breakpoint in an adult with refractory acute lymphoblastic leukemia. Blood Cells Mol Dis; 2010 Dec 15;45(4):324-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The rare t(5;11) with a new breakpoint in an adult with refractory acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosome Breakpoints. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 5. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965752.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


17. Nagai K, Hashimoto H, Itoh K, Matsushita A, Shimoji S, Kimura T, Inoue D, Mori M, Nagai Y, Tabata S, Yanagida M, Takahashi T: [Graft-versus-leukemia effect by lymphocytes from the first donor after second cord blood transplantation in a patient with T-lymphoblastic lymphoma]. Rinsho Ketsueki; 2010 Jun;51(6):413-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Graft-versus-leukemia effect by lymphocytes from the first donor after second cord blood transplantation in a patient with T-lymphoblastic lymphoma].
  • A 19-year-old girl with T-lymphoblastic lymphoma (T-LBL) was referred to our hospital because of refractory disease.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Graft vs Leukemia Effect / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. T-Lymphocytes. T-Lymphocytes, Cytotoxic / immunology. Tissue Donors
  • [MeSH-minor] Acute Disease. Asparaginase / therapeutic use. Bone Marrow Transplantation. Chronic Disease. Female. Graft vs Host Disease / immunology. Humans. Minor Histocompatibility Antigens. Transplantation Conditioning. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622488.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Minor Histocompatibility Antigens; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


18. Dudler C, Bargetzi M, Tichelli A, Gratwohl A, Passweg JR, Wernli M: DV-ICE, intensive induction and early transplantation for adult patients with acute lymphoblastic leukemia: a phase II study. Eur J Haematol; 2009 Dec 1;83(6):512-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DV-ICE, intensive induction and early transplantation for adult patients with acute lymphoblastic leukemia: a phase II study.
  • OBJECTIVES: Eighty percent of adult patients with acute lymphoblastic leukemia (ALL) achieve a complete remission (CR) but only 30-40% are long term survivors.
  • The role of induction intensity, first remission hematopoietic stem cell transplantation (HSCT) and maintenance chemotherapy continues to be discussed.
  • 11 patients did not receive a HSCT because of early death in nine (treatment toxicity in five, refractory disease in four), one patient refused transplantation, one patient was not suitable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Disease-Free Survival. Early Termination of Clinical Trials. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Hydrocortisone / administration & dosage. Hydrocortisone / adverse effects. Idarubicin / administration & dosage. Idarubicin / adverse effects. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Pilot Projects. Prospective Studies. Treatment Failure. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614953.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  •  go-up   go-down


19. Ishii H, Kawabata Y, Amemiya Y, Ogata M, Kadota J: Multiple tiny granulomatous lesions with eosinophils in a patient with smoldering-type adult T-cell leukaemia: the possibility of a new type of bronchioloalveolopathy. Respirology; 2010 Jan;15(1):182-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple tiny granulomatous lesions with eosinophils in a patient with smoldering-type adult T-cell leukaemia: the possibility of a new type of bronchioloalveolopathy.
  • We herein describe the first case, to our knowledge, of pulmonary lesions characterized by necrotizing granuloma formation with eosinophils, in a patient with smoldering-type adult T-cell leukaemia.
  • A 74-year-old man, diagnosed with smoldering-type adult T-cell leukaemia 1 year previously, was admitted due to repeated pyrexia and concurrent identification of diffuse small pulmonary nodules.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / pathology. Bronchioles / pathology. Eosinophils / pathology. Granuloma, Respiratory Tract / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lung Neoplasms / pathology. Pulmonary Alveoli / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895390.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


20. Evens AM, Ziegler SL, Gupta R, Augustyniak C, Gordon LI, Mehta J: Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma; 2007 Jul;7(7):472-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
  • Human T-lymphotrophic virus-1-associated adult T-cell leukemia/lymphoma (ATLL) is a rare and often fatal disease.
  • This study reports on a 55-year-old man with relapsed/refractory leukemic-phase ATLL including significant central nervous system (CNS) disease with resistance to previous zidovudine/IFN and arsenic trioxide/IFN treatment.
  • Further study examining denileukin diftitox in patients with relapsed/refractory ATLL is warranted.
  • [MeSH-major] Bone Marrow Transplantation. Central Nervous System Neoplasms / therapy. Diphtheria Toxin / administration & dosage. Hematologic Neoplasms / therapy. Interleukin-2 / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / therapy

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875237.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Oxides; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 4B9XT59T7S / Zidovudine; 9008-11-1 / Interferons; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


21. Serefhanoglu S, Goker H, Buyukasik Y, Sayinalp N, Ozcebe OI: Transformation of adult myelodysplastic syndrome-refractory anemia to acute T-cell lymphoblastic leukemia. J Natl Med Assoc; 2009 Apr;101(4):370-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of adult myelodysplastic syndrome-refractory anemia to acute T-cell lymphoblastic leukemia.
  • OBJECTIVE: Myelodysplastic syndrome (MDS) is recognized as a preleukemic disorder with a variable risk of transformation to acute myeloid leukemia.
  • Usually the blast cells in leukemia are transformed after MDS displays a myeloid phenotype.
  • Lymphoid progression had been reported as myeloid-lymphoid hybrid or early B phenotype, but our patient transformed acute T-lymphoblastic leukemia, which is a rare lymphoid transformation.
  • CLINICAL PRESENTATION AND INTERVENTION: We present a case of refractory anemia with excess of blast that transformed into acute T-cell lymphoblastic leukemia.
  • Twelve month later, he developed T-acute lymphoblastic leukemia.
  • The blasts were positive for expression of CD2, CD3, CD5, CD7, CD45, and HLA-DR, leading to a diagnosis of T-lymphoblastic leukemia.
  • This case clinically supports the nature of MDS as a pluripotent hematopoietic stem cell disorder.
  • MDS often transforms into acute leukemia, usually of a myeloid phenotype.
  • The transformation of MDS into acute lymphoblastic leukemia is extremely rare.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / complications. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / etiology


22. Zunino SJ, Storms DH, Ducore JM: Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Cancer Lett; 2010 Oct 1;296(1):49-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).
  • Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse.
  • Survival curves showed that leukemia cell growth was initially delayed by vincristine treatment, but the mice eventually succumbed to disease.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Leuk Lymphoma. 2005 May;46(5):681-91 [16019505.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Apr;63(5):761-7 [19034447.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4100-8 [12010813.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):85-95 [12691146.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Dec 30;141(3):956-62 [2880583.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):393-8 [2891436.001]
  • [Cites] Science. 1989 Dec 22;246(4937):1597-600 [2595371.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3658-61 [8101765.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):275-83 [8199015.001]
  • [Cites] Blood. 1996 May 1;87(9):3892-8 [8611717.001]
  • [Cites] Leukemia. 1996 Mar;10(3):558-63 [8642875.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1135-46 [8695830.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4332-7 [8813118.001]
  • [Cites] Blood. 1997 Sep 1;90(5):2015-9 [9292537.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Crit Rev Clin Lab Sci. 1998 Feb;35(1):1-57 [9532418.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Nov;133(11):875-93 [17671794.001]
  • (PMID = 20381955.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA122117; United States / NCI NIH HHS / CA / 1R21CA122117-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  • [Other-IDs] NLM/ NIHMS195255; NLM/ PMC2906616
  •  go-up   go-down


23. Kawano N, Ishikawa F, Shimoda K, Yasukawa M, Nagafuji K, Miyamoto T, Baba E, Tanaka T, Yamasaki S, Gondo H, Otsuka T, Ohshima K, Shultz LD, Akashi K, Harada M: Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/beta2-microglobulin(null) mice. Leukemia; 2005 Aug;19(8):1384-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/beta2-microglobulin(null) mice.
  • Adult T-cell leukemia (ATL) develops via multiple oncogenic steps in human T-cell leukemia virus type I (HTLV-I) carriers.
  • [MeSH-major] Disease Models, Animal. Leukemia-Lymphoma, Adult T-Cell / pathology. Neoplasm Transplantation
  • [MeSH-minor] Anemia, Refractory, with Excess of Blasts / pathology. Animals. Blood. Cell Proliferation. Clone Cells / pathology. Graft Survival. Humans. Leukemic Infiltration. Liver. Lymph Nodes. Mice. Mice, Inbred NOD. Mice, Knockout. Mice, SCID. Transplantation, Heterologous. beta 2-Microglobulin / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Leukemia (2005) 19, 1384-1390.
  • (PMID = 15959532.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI30389
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / beta 2-Microglobulin
  •  go-up   go-down


24. McGregor BA, Brown AW, Osswald MB, Savona MR: The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol; 2009 Apr;84(4):228-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
  • Clofarabine dosed at 52 mg/m2 was used in adult patients with refractory ALL to maximize response before allo-HSCT.
  • Published pharmacokinetic analysis revealed no difference in peak plasma or intracellular concentrations at clofarabine dosed above 40 mg/m2, yet inhibition of replication in leukemia cells was only sustained over 24 hr at 55 mg/m2.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Arabinonucleosides / therapeutic use. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic / statistics & numerical data. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Drug Evaluation. Etoposide / administration & dosage. Fatal Outcome. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Transplantation. Humans. Idarubicin / administration & dosage. Male. Mitoxantrone / administration & dosage. Recombinant Proteins. Recurrence. Remission Induction. Reoperation. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19260120.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antimetabolites, Antineoplastic; 0 / Arabinonucleosides; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 762RDY0Y2H / clofarabine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; PVI5M0M1GW / Filgrastim; ZRP63D75JW / Idarubicin; CVAD protocol; Ida-FLAG protocol
  • [Number-of-references] 22
  •  go-up   go-down


25. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res; 2006 Sep 1;12(17):5165-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
  • PURPOSE: Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth and division.
  • A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies.
  • RESULTS: Twenty-seven patients (9 acute myelogenous leukemia, 5 myelodysplastic syndrome, 6 B-chronic lymphocytic leukemia, 4 mantle cell lymphoma, 1 myelofibrosis, 1 natural killer cell/T-cell leukemia, and 1 T-cell prolymphocytic leukemia) received everolimus.
  • One patient with refractory anemia with excess blasts achieved a major platelet response of over 3-month duration.
  • A second patient with refractory anemia with excess blasts showed a minor platelet response of 25-day duration.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Myelodysplastic Syndromes / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / antagonists & inhibitors. Administration, Oral. Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Everolimus. Female. Humans. Killer Cells, Natural / immunology. Male. Maximum Tolerated Dose. Middle Aged. Phosphoproteins / antagonists & inhibitors. Phosphorylation. Protein Kinases / drug effects. Protein Kinases / metabolism. Recurrence. Ribosomal Protein S6 Kinases, 70-kDa / antagonists & inhibitors. Signal Transduction / drug effects. T-Lymphocytes / immunology. TOR Serine-Threonine Kinases. Treatment Outcome. Vasculitis, Leukocytoclastic, Cutaneous / chemically induced

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951235.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA55164
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


26. Brethon B, Auvrignon A, Galambrun C, Yakouben K, Leblanc T, Bertrand Y, Leverger G, Baruchel A: Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia. BMC Cancer; 2006;6:172
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
  • BACKGROUND: Gemtuzumab ozogamicin (GO) is a cytotoxic anti-CD33 monoclonal antibody that has given promising preliminary results in adult myeloid CD33+ AML.
  • Three patients (2 MDS/AML, 1 JMML) were refractory to first-line treatment, 8 patients with de novo AML were in refractory first relapse, and one patient with de novo AML was in 2nd relapse after stem cell transplantation (SCT).
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Immunotoxins / therapeutic use. Leukemia, Myeloid / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2705-13 [11352963.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1490-6 [11410481.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):406-13 [11466696.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):47-58 [11792178.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2310-4 [11895761.001]
  • [Cites] Clin Lymphoma. 2002 Mar;2 Suppl 1:S29-34 [11970768.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2774-82 [12065553.001]
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(1):23-8 [12105773.001]
  • [Cites] Blood. 2003 May 15;101(10):3868-71 [12543868.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1578-82 [12738663.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4277-83 [12933575.001]
  • [Cites] Onkologie. 2004 Jun;27(3):269-72 [15249716.001]
  • [Cites] J Exp Med. 1989 May 1;169(5):1721-31 [2469766.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):416-22 [1671875.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):364-70 [1346800.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1046-54 [8501490.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3336-42 [8324745.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3097-108 [7579404.001]
  • [Cites] Med Pediatr Oncol. 1996 Mar;26(3):173-9 [8544799.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):647-55 [9722289.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3678-84 [10339474.001]
  • [Cites] Med Pediatr Oncol. 1999 Jun;32(6):411-5 [10358698.001]
  • [Cites] Br J Haematol. 1999 Sep;106(4):851-9 [10519984.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):321-31 [11378544.001]
  • (PMID = 16805911.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  • [Other-IDs] NLM/ PMC1523361
  •  go-up   go-down


27. Gidwani P, Ramesh KH, Liu Y, Kolb EA: The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. Chemotherapy; 2008;54(2):120-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
  • Clofarabine, a purine nucleoside analog, has recently been approved for use in relapsed and refractory pediatric acute lymphoblastic leukemia.
  • Clofarabine and cytarabine together may be synergistic and have been used safely in adult leukemia patients.
  • CASE REPORT: We describe the administration of this combination to a 9-year-old boy with multiple relapsed T-cell acute lymphoblastic leukemia who failed to achieve remission after the third attempt.
  • CONCLUSION: This case is the first report of successful remission induction in a multiple relapsed pediatric leukemia patient using the clofarabine and cytarabine combination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303261.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 04079A1RDZ / Cytarabine; 762RDY0Y2H / clofarabine
  •  go-up   go-down


28. Tageja N, Mohammad M, Bentley G, Bishop C: Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report. Case Rep Med; 2010;2010:729790
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report.
  • Adult T-cell Leukemia/Lymphoma (ATL) is rarely seen in the U.S. and Europe, usually limited to African Americans from the southeastern U.S. and immigrants from HTLV-1 endemic areas.
  • Reaching an accurate and timely diagnosis of ATL in such nonendemic areas can be challenging, owing to limited exposure, diverse manifestations, and varying cell morphology.
  • We present a case of chronic adult T-cell leukemia (ATL) with Chronic Lymphocytic Leukemia- (CLL-) like morphology that remained untreated for ten years and then developed treatment refractory acute ATL crisis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1994 Feb;86(2):383-5 [8199030.001]
  • [Cites] Br J Haematol. 1999 May;105(2):369-75 [10233406.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] Leuk Lymphoma. 1993 Dec;12(1-2):123-30 [8161929.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Clin Pathol. 1989 Jun;42(6):567-84 [2738163.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):185-96 [18081707.001]
  • (PMID = 20368783.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2846349
  •  go-up   go-down


29. Shu ST, Nadella MV, Dirksen WP, Fernandez SA, Thudi NK, Werbeck JL, Lairmore MD, Rosol TJ: A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma. Cancer Res; 2007 Dec 15;67(24):11859-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma.
  • Adult T-cell /lymphomaleukemia (ATLL) is caused by human T-cell lymphotropic virus type 1 (HTLV-1).
  • We found that PS-341 decreased cell viability, increased apoptosis, and down-regulated PTHrP expression in ATLL cells in vitro.
  • Bioluminescent imaging and tumor cell count showed a significant reduction in tumor burden in mice from all treatment groups.
  • Our results indicate that both PS-341 and Zol are effective treatments for ATLL and HHM, which are refractory to conventional therapy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] Endocrinology. 2002 Feb;143(2):596-606 [11796515.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1083-6 [11861386.001]
  • [Cites] Regul Pept. 2002 May 15;105(2):109-20 [11891011.001]
  • [Cites] Blood. 2003 Jul 1;102(1):311-9 [12649140.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1105-11 [15176993.001]
  • [Cites] Blood. 2004 Aug 1;104(3):802-9 [15090453.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Cancer. 1985 Feb 1;55(3):615-9 [2981152.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5276-89 [8355682.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1708-11 [7934167.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):395-400 [7812198.001]
  • [Cites] Medicina (B Aires). 1997;57 Suppl 1:65-75 [9567358.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4747-51 [9616173.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):419-30 [15543232.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1175-83 [15889157.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6005-15 [16155607.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1896-904 [16167056.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4294-302 [16118323.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):200-5 [16254204.001]
  • [Cites] Clin Exp Metastasis. 2006;23(1):19-31 [16715352.001]
  • [Cites] Br J Haematol. 2006 Dec;135(5):688-92 [17107351.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):424-32 [17233845.001]
  • [Cites] Oncology. 2006;70(6):474-82 [17283449.001]
  • [Cites] Blood. 2007 Jul 1;110(1):334-8 [17371942.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1752-62 [17554373.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1098-104 [17494860.001]
  • [Cites] Blood. 2000 Jul 15;96(2):671-5 [10887133.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 6):35-44 [11346863.001]
  • (PMID = 18089816.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCRR NIH HHS / RR / RR014324-05; United States / NCRR NIH HHS / RR / T32 RR007073-07; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCI NIH HHS / CA / CA100730-05; United States / NCRR NIH HHS / RR / T32 RR007073; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / RR007073; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCRR NIH HHS / RR / T32 RR007073-06; United States / NCI NIH HHS / CA / CA77911; United States / NCRR NIH HHS / RR / RR007073-06; United States / NCRR NIH HHS / RR / R01 RR014324-05; United States / NCI NIH HHS / CA / P01 CA100730-05; United States / NCRR NIH HHS / RR / RR007073-07; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ NIHMS94364; NLM/ PMC2832603
  •  go-up   go-down


30. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood; 2007 Jan 1;109(1):31-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
  • The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL).

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):166-73 [16330674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3921-6 [15001702.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1288-95 [15141228.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):421-8 [15314509.001]
  • [Cites] South Med J. 1986 Oct;79(10):1210-5 [2945258.001]
  • [Cites] N Engl J Med. 1987 Feb 5;316(6):297-303 [3543674.001]
  • [Cites] Blood. 1997 Jan 1;89(1):32-40 [8978274.001]
  • [Cites] Exp Hematol. 2005 Jan;33(1):53-61 [15661398.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Curr Opin Hematol. 2005 Jul;12(4):273-8 [15928483.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):150-8 [16007885.001]
  • [Cites] J Invest Dermatol. 2005 Nov;125(5):1045-52 [16297208.001]
  • [Cites] Eur J Haematol. 2006 Jan;76(1):42-50 [16343270.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5165-70 [11016644.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2456-71 [11331325.001]
  • [Cites] Arch Dermatol. 2001 May;137(5):581-93 [11346336.001]
  • [Cites] Cell Mol Life Sci. 2001 May;58(5-6):728-36 [11437234.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1321-30 [11696577.001]
  • [Cites] J Am Acad Dermatol. 2002 Jan;46(1):95-106 [11756953.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):194-202 [11902574.001]
  • [Cites] Clin Lymphoma. 2002 Mar;2(4):222-8 [11970761.001]
  • [Cites] Nat Rev Drug Discov. 2002 Apr;1(4):287-99 [12120280.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1497-504 [12168829.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1):35-49 [12833006.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [ErratumIn] Blood. 2007 Jun 15;109(12):5086
  • (PMID = 16960145.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA086815
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Other-IDs] NLM/ PMC1785068
  •  go-up   go-down


31. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS: A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma; 2010 Mar;51(3):447-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
  • The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable.
  • Patients with newly diagnosed (n = 27) or refractory/relapsed (n = 11) PTCL received a combination of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin.
  • In relapsed/refractory patients the median OS was 6.1 months.
  • Treatment-related deaths occurred in six newly diagnosed patients and one with relapsed/refractory disease.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, T-Cell / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Treatment Outcome

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141439.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


32. Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC: Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol; 2005 Mar;33(3):286-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
  • OBJECTIVES: We and others have shown that B cell precursor acute lymphoblastic leukemia cells (ALL) stimulated with CD40 ligand become efficient antigen-presenting cells (APC) capable of expanding autologous, tumor-specific T cells from patients.
  • PATIENTS AND METHODS: Nine patients with relapsed/refractory ALL were enrolled in a phase I trial of vaccination with autologous CD40-ALL.
  • Despite recovery of myelopoiesis, most patients had profound defects in T, B, and natural killer (NK) cell numbers that failed to recover at any point during therapy.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy, Adoptive. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antigen-Presenting Cells / immunology. Antigens, CD40 / immunology. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Secondary Prevention. T-Lymphocytes / immunology. T-Lymphocytes / transplantation. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730852.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K08HL72750; United States / NCI NIH HHS / CA / P01CA68484
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Cancer Vaccines
  •  go-up   go-down


33. Reilly KM, Kisor DF: Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther; 2009;2:219-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
  • Clinical responses to nelarabine have been demonstrated in various T-cell malignancies and appear to correlate with a relatively high intracellular concentration of ara-GTP compared to nonresponders.
  • Therefore, this unique drug feature of nelarabine accounts for clinical utilization in treating adult and pediatric patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1993 Aug;7(8):1261-7 [8350627.001]
  • [Cites] Ann N Y Acad Sci. 1993 Jun 23;685:225-36 [8363226.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2107-13 [9815603.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4937-43 [10519407.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):995-1003 [10694549.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:123-30 [16304369.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):535-40 [17158775.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1098-105 [18309944.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1842-8 [12750168.001]
  • (PMID = 20616909.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2886323
  • [Keywords] NOTNLM ; 9-beta-D-arabinofuranosyl guanine / T-cell acute lymphoblastic leukemia / ara-G / nelarabine
  •  go-up   go-down


34. Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, Yavuzsen T, Yuksel E, Undar B: The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymphoma; 2007 Jul;48(7):1372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At a median follow-up of 24 months, 22 patients (19.5 %) transformed to acute myelogenous leukaemia (AML).
  • In WHO classification, significant differences were observed in both OS and leukaemia free survival (LFS) between patients with RA/RARS and refractory cytopenia with multi-lineage dysplasia/refractory cytopenia with multi-lineage dysplasia and ringed sideroblasts (RCMD/RS-RCMD) (p = 0.0001).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Classification. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Turkey / epidemiology. World Health Organization


35. Bieber MM, Twist CJ, Bhat NM, Teng NN: Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro. Pediatr Blood Cancer; 2007 Apr;48(4):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
  • This study investigated if this mAb could bind and kill acute lymphoblastic leukemia (ALL) B-progenitor lymphoblasts in vitro.
  • ALL cell lines were used to determine if combining mAb 216 with chemotherapeutic drugs would enhance killing and cell lines were used to measure cytotoxicity by mAb 216 with human complement.
  • PROCEDURE: Expression of cell surface markers and mAb 216 epitope on fresh and banked ALL bone marrow samples was determined by flow cytometry.
  • Cytotoxicity of ALL cell lines incubated with mAb 216 and vincristine (VCR) or human complement was determined using flow cytometry.
  • Incubation of mAb 216 with human complement increased cytotoxicity of ALL cell lines.
  • CONCLUSION: This increased cytotoxicity with chemotherapy and the functional ability of mAb 216 to use multiple pathways to induce cell death identify mAb 216 as a potentially novel therapeutic tool in the treatment of B-progenitor ALL.
  • Based on the results from this preclinical study, a Phase I clinical trial with mAb 216 for the treatment of patients with relapsed or refractory B-lineage ALL is ongoing.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow / immunology. Bone Marrow / pathology. Cell Line, Tumor / drug effects. Cell Line, Tumor / immunology. Child. Complement System Proteins / immunology. Drug Screening Assays, Antitumor. Hematopoietic Stem Cells / drug effects. Hematopoietic Stem Cells / immunology. Humans. Immunophenotyping. Immunotherapy. Leukemia, Myeloid / immunology. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / pathology. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / immunology. Specimen Handling. Tissue Preservation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421902.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


36. Robak T, Szmigielska-Kapłon A, Błoński JZ, Kasznicki M, Chojnowski K: Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies. Chemotherapy; 2005 Aug;51(5):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We determined the effectiveness and toxicity of combined chemotherapy consisting of etoposide 100 mg/m(2)/day i.v. and cladribine (2-CdA) 0.12 mg/kg/day i.v. each for 5 days (EC regimen) in the treatment of refractory or relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cladribine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infection / chemically induced. Infusions, Intravenous. Male. Middle Aged. Neutropenia / chemically induced. Recurrence. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16088121.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 6PLQ3CP4P3 / Etoposide; EC regimen 2
  •  go-up   go-down


37. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D: Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood; 2010 Sep 9;116(10):1795-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
  • Forty patients were enrolled in this phase 2 study combining radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic hematopoietic cell transplantation (HCT) from related (n = 13) or unrelated (n = 27) donors for the treatment of advanced non-Hodgkin lymphoma.
  • Diagnoses were follicular lymphoma (n = 17), chronic lymphocytic leukemia (n = 13), mantle cell lymphoma (n = 8), marginal zone lymphoma (n = 1), and lymphoplasmacytic lymphoma (n = 1).
  • All patients were high risk with refractory disease or relapse after preceding autologous HCT.
  • Twenty-two of 40 patients (55%) are alive, resulting in a Kaplan-Meier-estimated 2-year survival of 51% for all, 67% for follicular lymphoma, 49% for chronic lymphocytic leukemia, and 37% for mantle cell lymphoma patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, Non-Hodgkin / surgery. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / chemistry. Combined Modality Therapy. Female. Graft vs Host Disease / etiology. Hematologic Diseases / etiology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome. Yttrium Radioisotopes / chemistry. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530284.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00302757
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


38. Miyamura F, Kako S, Yamagami H, Sato K, Sato M, Terasako K, Kimura S, Nakasone H, Aoki S, Okuda S, Yamazaki R, Oshima K, Yoshinaga K, Higuchi T, Nishida J, Demitsu T, Kakehashi A, Kanda Y: Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation. Int J Hematol; 2009 Oct;90(3):397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation.
  • Only some carriers of human T cell lymphotropic virus type I (HTLV-1) develop adult T cell leukemia/lymphoma (ATLL) after a long latency period, and an association has been reported between chronic refractory eczema, known as infective dermatitis, and young-onset ATLL.
  • A 25-year-old female developed ATLL and underwent allogeneic hematopoietic stem cell transplantation (HSCT) in non-remission.
  • She had chronic refractory eczema and corneal injury at the onset of ATLL.
  • [MeSH-major] Corneal Diseases / therapy. Eczema / therapy. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Chronic Disease. Female. HTLV-I Infections / complications. Human T-lymphotropic virus 1. Humans. Transplantation, Homologous. Treatment Outcome. Viral Load


39. Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T: A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int J Hematol; 2009 Jun;89(5):679-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.
  • A Phase I/II dose-escalation study was designed to evaluate the efficacy, safety, and pharmacokinetics of nilotinib in Japanese patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Asian Continental Ancestry Group. Benzamides. Drug Resistance, Neoplasm. Female. Fusion Proteins, bcr-abl / antagonists & inhibitors. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / pharmacokinetics. Piperazines / toxicity. Protein-Tyrosine Kinases / antagonists & inhibitors. Salvage Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1765-9 [16721371.001]
  • [Cites] Semin Hematol. 1988 Jan;25(1):49-61 [3279515.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1330-40 [10219069.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1834-9 [18048643.001]
  • [Cites] N Engl J Med. 1999 Jul 15;341(3):164-72 [10403855.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3540-6 [17715389.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1054-61 [19282833.001]
  • (PMID = 19449194.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


40. Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL: A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia; 2009 Dec;23(12):2259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
  • This Phase I study of clofarabine with etoposide and cyclophosphamide for children with relapsed/refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) was conducted to determine the maximum tolerated dose (MTD), dose-limiting toxicities and the recommended phase 2 doses (RP2Ds).
  • Of the 16 responders, 9 patients proceeded to hematopoietic stem cell transplantation.
  • In conclusion, the combination of clofarabine, etoposide and cyclophosphamide was well tolerated and effective in pediatric patients with relapsed/refractory leukemia.
  • [MeSH-major] Adenine Nucleotides / administration & dosage. Arabinonucleosides / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Leukemia / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Child. Child, Preschool. Drug-Induced Liver Injury. Hematopoietic Stem Cell Transplantation. Humans. Infant. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Maximum Tolerated Dose. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19741725.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 6PLQ3CP4P3 / Etoposide; 762RDY0Y2H / clofarabine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


41. Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, Eckhardt SG: The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia; 2007 Apr;21(4):739-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
  • The effects of tipifarnib on cell proliferation, induction of apoptosis and inhibition of Pgp-mediated anthracycline efflux were analyzed in two human leukemia cell lines overexpressing Pgp (CCRF-CEM and KG1a).
  • In high risk and refractory patients these properties may be exploited as a dual targeting mechanism in the therapy of AML.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Calcium Channel Blockers / pharmacokinetics. Cell Line, Tumor. Clone Cells. Humans. Leukemia-Lymphoma, Adult T-Cell. Verapamil / pharmacokinetics

  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268526.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA079446; United States / NCI NIH HHS / CA / CA099176; United States / NCI NIH HHS / CA / CA106349
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Calcium Channel Blockers; 0 / P-Glycoprotein; 0 / Quinolones; 192185-72-1 / tipifarnib; CJ0O37KU29 / Verapamil; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


42. Terasawa T, Dahabreh IJ, Nihashi T: Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist; 2010;15(7):750-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
  • BACKGROUND: We conducted a systematic review and meta-analysis to better define the prognostic ability of fluorine-18-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) following salvage chemotherapy for relapsed or refractory Hodgkin's lymphoma (HL) and aggressive non-Hodgkin's lymphoma.
  • The most commonly evaluated histologies were diffuse large B-cell lymphoma (n = 313) and HL (n = 187), which were typically treated with various salvage and high-dose chemotherapy regimens.
  • CONCLUSION: (18)F-FDG PET performed after salvage therapy appears to be an appropriate test to predict treatment failure in patients with refractory or relapsed lymphoma who receive high-dose chemotherapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4652-61 [15837965.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):1066-74 [16047335.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6400-8 [16155026.001]
  • [Cites] J Clin Epidemiol. 2005 Oct;58(10):982-90 [16168343.001]
  • [Cites] Bone Marrow Transplant. 2006 Aug;38(3):211-6 [16770314.001]
  • [Cites] Blood. 2007 Jan 15;109(2):486-91 [17003382.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Biostatistics. 2007 Apr;8(2):239-51 [16698768.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2481-9 [17497648.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1361-9 [17623832.001]
  • [Cites] J Nucl Med. 2008 Jan;49(1):13-21 [18077527.001]
  • [Cites] Stat Med. 2008 Feb 28;27(5):687-97 [17611957.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):206-19 [18300772.001]
  • [Cites] Leuk Lymphoma. 2008 Apr;49(4):727-33 [18398740.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2496-503 [18833583.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1776-80 [19050068.001]
  • [Cites] Ann Oncol. 2009 Feb;20(2):309-18 [18842613.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1906-14 [19273713.001]
  • [Cites] Br J Cancer. 2009 Apr 21;100(8):1219-29 [19367280.001]
  • [Cites] Oncologist. 2009 Apr;14(4):425-32 [19342476.001]
  • [Cites] Br J Haematol. 2009 May;145(3):369-72 [19344403.001]
  • [Cites] Bone Marrow Transplant. 2009 Jun;43(12):941-8 [19139730.001]
  • [Cites] Leuk Lymphoma. 2009 Aug;50(8):1257-60 [19544140.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):156-62 [19727713.001]
  • [Cites] Blood. 2010 Jan 28;115(4):775-7; quiz 918 [19767508.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] Leukemia. 2002 Feb;16(2):260-7 [11840293.001]
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(2):103-11 [12132049.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Chest. 2003 Aug;124(2):608-13 [12907550.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Blood. 2003 Sep 15;102(6):1989-96 [12676776.001]
  • [Cites] BMC Med Res Methodol. 2003 Nov 10;3:25 [14606960.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):925-32 [15504635.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Stat Med. 1998 Dec 30;17(24):2815-34 [9921604.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4 [16106022.001]
  • (PMID = 20587551.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR025752-02S1; United States / NCRR NIH HHS / RR / UL1 RR025752; United States / NCRR NIH HHS / RR / UL1 RR025752-02S1; United States / NCRR NIH HHS / RR / UL1RR025752
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS250419; NLM/ PMC2992843
  •  go-up   go-down


43. Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ: Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer; 2006 Oct 1;107(7):1542-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
  • Fifty-four adult patients with recurrent or refractory, low-grade non-Hodgkin lymphoma (LG-NHL) and B-cell chronic lymphocytic leukemia (B-CLL) were treated according to the RC/RCC regimens.
  • RESULTS: Thirty-three patients with B-CLL, 12 patients with LG-NHL and 9 patients with mantle cell lymphoma (MCL) entered the study.
  • Thirty-three patients (61%) had recurrent disease after prior therapy, and 21 patients (39%) had refractory disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Cladribine / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Lymphoproliferative Disorders / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16948126.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


44. Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Gräf T, Haas R, Kobbe G: Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant; 2009 Dec;44(12):785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
  • In this prospective study, we examined the toxicity and efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk acute lymphoblastic leukemia who undergo allogeneic hematopoietic stem cell transplantation.
  • Fifteen patients received fludarabine 30 mg/m(2), cytarabine 2000 mg/m(2), amsacrine 100 mg/m(2) on days -10, -9, -8 and -7, anti-thymocyte globulin (ATG-Fresenius) 20 mg/kg body weight on days -6, -5 and -4 and fractionated total body irradiation 2 x 2 Gy on days -3, -2 and -1 (FLAMSA-ATG-TBI) before allogeneic hematopoietic stem cell transplantation.
  • At the time of hematopoietic stem cell transplantation, 10 patients were in complete remission (8 CR1; 2 CR2), 3 with primary refractory and 2 suffered from refractory relapse.
  • All patients achieved a complete remission after hematopoietic stem cell transplantation; and after a median follow-up time of 1091 days (range, 334-1554 days), nine patients (60%) are alive and free from disease, including three patients with prior refractory disease.
  • Thus, conditioning with the FLAMSA-ATG-TBI regimen is a feasible and effective alternative for patients with relapsed or high-risk acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Amsacrine / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Recurrence. Risk Factors. Survival Rate. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430496.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


46. Gandhi V, Plunkett W: Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol; 2006 Nov;18(6):584-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Both clofarabine and nelarabine recently received an accelerated approval by the US Food and Drug Administration for use in refractory or relapsed pediatric acute lymphoblastic leukemia and in refractory-relapsed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
  • Studies in cell lines have demonstrated that triphosphate is the active metabolite for both these purine nucleoside analogs.
  • Several phase I and II clinical explorations have suggested the utility of clofarabine in acute leukemias and nelarabine in T-cell diseases.
  • SUMMARY: Clofarabine is the first deoxyadenosine analog that shows promise in adult and pediatric acute leukemias without untoward toxicity.
  • Nelarabine, as expected from its design, is a drug that may be directed to T-cell diseases.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988579.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57629; United States / NCI NIH HHS / CA / CA81534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 60158CV180 / nelarabine; 762RDY0Y2H / clofarabine
  • [Number-of-references] 68
  •  go-up   go-down


47. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN: Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant; 2009 May;15(5):554-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.
  • We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004.
  • Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease.
  • Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1460-8 [15084619.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1923-30 [15191952.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] N Engl J Med. 1993 Mar 4;328(9):593-602 [8429851.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1050-5 [8049425.001]
  • [Cites] Am J Med. 1996 Mar;100(3):299-307 [8629675.001]
  • [Cites] Biol Blood Marrow Transplant. 1997 Aug;3(3):150-6 [9310192.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1832-6 [9716615.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1177-85 [9780337.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Ann Oncol. 1999 May;10(5):527-32 [10416001.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3797-803 [15280203.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Transfus Apher Sci. 2005 Feb;32(1):45-53 [15737873.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6163-71 [16135483.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):223-30 [16197454.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Blood Rev. 2006 Sep;20(5):235-44 [16513231.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64 [16920562.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34 [17162215.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):85-90 [17336258.001]
  • [Cites] Blood. 2007 May 15;109(10):4586-8 [17234738.001]
  • [Cites] Haematologica. 2007 May;92(5):627-34 [17488686.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Dec;13(12):1499-507 [18022580.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Feb;14(2):236-45 [18215784.001]
  • [Cites] Br J Haematol. 2008 Apr;141(2):235-43 [18318762.001]
  • [Cites] Cancer. 2008 May 1;112(9):1992-2001 [18311781.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):775-82 [18541196.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5530-6 [18411419.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(8):859-64 [11081385.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • (PMID = 19361747.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-14; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / CA076518-14; United States / NHLBI NIH HHS / HL / U01 HL069294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS219378; NLM/ PMC3120935
  •  go-up   go-down


48. Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K: HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood; 2005 Dec 15;106(13):4294-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One in 20 carriers of human T-cell leukemia virus type 1 (HTLV-1) will develop adult T-cell leukemia/lymphoma (ATL), a disease frequently associated with hypercalcemia, bone destruction, and a fatal course refractory to current therapies.
  • Overexpression of the HTLV-1-encoded Tax oncoprotein under the human granzyme B promoter causes large granular lymphocytic leukemia/lymphomas in mice.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1997 Apr 18;89(2):309-19 [9108485.001]
  • [Cites] Annu Rev Immunol. 1997;15:15-37 [9143680.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1557-63 [9362422.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):593-602 [9469347.001]
  • [Cites] Methods. 1998 Sep;16(1):83-94 [9774518.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:919-30 [15569630.001]
  • [Cites] J Bone Miner Res. 2005 Jan;20(1):58-66 [15619670.001]
  • [Cites] Skeletal Radiol. 1985;14(3):194-7 [2997937.001]
  • [Cites] J Clin Invest. 1987 Sep;80(3):911-6 [2887587.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):197-206 [9916131.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3305-11 [15292059.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):185-95 [15324701.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2852-9 [15353320.001]
  • [Cites] Calcif Tissue Int. 2004 Jul;75(1):71-7 [15037971.001]
  • [Cites] Am J Pathol. 1988 Sep;132(3):593-7 [3414786.001]
  • [Cites] J Bone Miner Res. 1987 Dec;2(6):595-610 [3455637.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6876-81 [3180096.001]
  • [Cites] Endocrinology. 1989 Oct;125(4):1805-13 [2676473.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1989 Nov-Dec;83(6):729-31 [2617642.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Blood. 1991 Jun 1;77(11):2451-5 [2039827.001]
  • [Cites] Science. 1991 Aug 30;253(5023):1026-8 [1887217.001]
  • [Cites] J Virol. 1991 Oct;65(10):5471-6 [1895396.001]
  • [Cites] Virology. 1993 Nov;197(1):196-204 [8212554.001]
  • [Cites] Blood. 1994 Nov 1;84(9):2904-11 [7949164.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] Baillieres Clin Haematol. 1995 Mar;8(1):131-48 [7663044.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S162-9 [8797719.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1544-9 [8833902.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):525-40 [15580311.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1129-35 [15734993.001]
  • [Cites] Leukemia. 2005 Apr;19(4):664-70 [15744346.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1082-90 [10699899.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2961-78 [10898340.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2979-88 [10898341.001]
  • [Cites] J Virol. 2000 Dec;74(23):11394-7 [11070040.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1677-81 [11080809.001]
  • [Cites] J Clin Invest. 2000 Dec;106(12):1481-8 [11120755.001]
  • [Cites] J Virol. 2001 Mar;75(5):2185-93 [11160722.001]
  • [Cites] Blood. 2002 Jan 1;99(1):88-94 [11756157.001]
  • [Cites] Blood. 2002 Jan 15;99(2):634-40 [11781248.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 18;290(2):650-5 [11785948.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):561-7 [12007504.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] J Dermatol. 2002 Oct;29(10):644-7 [12432996.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1559-72 [12438453.001]
  • [Cites] J Exp Med. 2003 Jan 20;197(2):163-8 [12538656.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):748-57 [12548572.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 21):19-27 [12584691.001]
  • [Cites] Curr Rheumatol Rep. 2003 Feb;5(1):65-74 [12590887.001]
  • [Cites] J Bone Miner Res. 2003 Mar;18(3):482-92 [12619933.001]
  • [Cites] Blood. 2003 Jul 1;102(1):200-6 [12623838.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9506-11 [12881486.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):204-11 [12970722.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1468-76 [14504045.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6170-3 [14559799.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S19-31 [14600589.001]
  • [Cites] Breast. 2003 Aug;12 Suppl 2:S22-9 [14659140.001]
  • [Cites] J Bone Miner Res. 2004 Feb;19(2):278-88 [14969398.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1105-11 [15176993.001]
  • [Cites] Blood. 2004 Aug 1;104(3):802-9 [15090453.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):583-92 [15287953.001]
  • [Cites] Jpn J Cancer Res. 1996 Sep;87(9):887-92 [8878449.001]
  • [Cites] N Engl J Med. 1996 Dec 12;335(24):1785-91 [8965890.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8 [8931609.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):272-80 [9117461.001]
  • (PMID = 16118323.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100730; United States / NIDDK NIH HHS / DK / P30 DK056341; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P30 CA091842; United States / NIDDK NIH HHS / DK / DK56341
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Interleukin-6; 0 / Lymphokines; 0 / Organophosphonates; 64060-24-8 / osteoclast activating factor
  • [Other-IDs] NLM/ PMC1895233
  •  go-up   go-down


49. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH: Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev; 2005 Nov;19(6):289-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
  • Acute lymphoblastic leukaemia (ALL) responds well to chemotherapy and the majority of children and a significant proportion of adults are cured of their disease after primary therapy.
  • A significant number of patients with ALL develop disease that is refractory to further therapy.
  • The infusion of unmodified donor lymphocytes (DLI) following relapse after allogeneic transplantation has been shown to be curative in patients with chronic myeloid leukaemia (CML).
  • Other approaches include exploiting the expression of leukaemia-specific antigens such as the proteinase PR-3 or the zinc finger transcription factor Wilms tumour-1 protein (WT-1) to stimulate CTL responses.
  • In vivo studies to date suggest that educated T-cells may have a role to play in the treatment of relapsed and refractory ALL in the future.
  • [MeSH-major] Immunotherapy, Adoptive. Lymphocyte Transfusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adult. Child. Child, Preschool. Dendritic Cells / immunology. Dendritic Cells / transplantation. Female. Graft vs Leukemia Effect / immunology. Humans. Male. Neoplasm Proteins / immunology. Secondary Prevention. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / transplantation. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / transplantation. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275419.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 89
  •  go-up   go-down


50. Ochsenreither S, Reinwald M, Thiel E, Burmeister T: Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine. Mol Diagn Ther; 2010 Jun 01;14(3):185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.
  • A human erythroleukemia cell line (HEL) was used as a positive control in a 3-fold lower concentration than the negative control because of the gene amplification of the mutated JAK2 kinase in this cell line.
  • Additionally, samples were analyzed using an amplification refractory mutation system (ARMS).
  • A homozygotic mutated cell line or plasmids should be used for dilution standards.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Substitution / genetics. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Health Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2006 Apr;125(4):625-33 [16627272.001]
  • [Cites] Cancer Biomark. 2007;3(6):315-24 [18048969.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2162-8 [15920007.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4030-6 [17712047.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] Leukemia. 2006 Mar;20(3):471-6 [16408098.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2037-40 [16709929.001]
  • [Cites] Lancet. 2005 Dec 3;366(9501):1945-53 [16325696.001]
  • [Cites] Leukemia. 2008 Jan;22(1):14-22 [17882280.001]
  • [Cites] Leuk Lymphoma. 2009 Feb;50(2):247-53 [19235016.001]
  • [Cites] Haematologica. 2009 Jan;94(1):38-45 [19001280.001]
  • [Cites] Hematol Oncol. 2006 Dec;24(4):227-33 [17006961.001]
  • [Cites] Science. 1982 Jun 11;216(4551):1233-5 [6177045.001]
  • [Cites] Leukemia. 2006 Jan;20(1):168-71 [16270039.001]
  • [Cites] J Mol Diagn. 2006 Jul;8(3):330-4 [16825505.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22788-92 [15863514.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):313-4 [16321863.001]
  • [Cites] Haematologica. 2008 Jan;93(1):41-8 [18166784.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1055-60 [16572198.001]
  • [Cites] Cancer. 2009 Sep 1;115(17):3842-7 [19472396.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1952-9 [17625606.001]
  • [Cites] Blood. 2007 Aug 1;110(3):840-6 [17379742.001]
  • [Cites] Eur J Haematol. 2007 Dec;79(6):508-15 [17961178.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Haematologica. 2007 Dec;92(12):1699-702 [18055996.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):397-411; quiz 526 [16931578.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Leukemia. 2006 Feb;20(2):350-3 [16341032.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1847-9 [16079890.001]
  • [Cites] Transplantation. 2007 Jun 15;83(11):1518-20 [17565328.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):997-1003 [16831057.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1316-21 [17018857.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1207-9 [15860661.001]
  • (PMID = 20560681.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


51. Brentjens RJ: Cellular therapies in acute lymphoblastic leukemia. Curr Opin Mol Ther; 2009 Aug;11(4):375-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular therapies in acute lymphoblastic leukemia.
  • The majority of adult patients with acute lymphoblastic leukemia (ALL) will die from the disease.
  • Although the prognosis for pediatric patients is significantly better than for adult patients with ALL, the prognosis for patients with relapsed or refractory disease is poor in all cases.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a related donor offers a significant therapeutic benefit for pediatric patients, although the benefit of this therapy to adults with ALL is less established.
  • Although treatment with donor-derived T-cells, so-called 'donor lymphocyte infusion', has demonstrated poor outcomes in patients with relapsed ALL following HSCT, modified adoptive T-cell regimens, including the infusion of enriched tumor-targeted donor T-cells and genetically targeted T-cells, are currently under clinical investigation.
  • In addition, the resistance of ALL tumor cell lines to NK-cell-mediated lysis may be overcome by the genetic modification of NK cells to target ALL tumor cell antigens, and this approach will be evaluated in an upcoming clinical trial.
  • Whether these novel adoptive cell therapies will ultimately result in improved clinical outcomes remains to be determined.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 15;105(4):1622-31 [15507526.001]
  • [Cites] Ann Hematol. 2004 Oct;83(10):667-9 [15300405.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Feb;15(2):257-65 [19167686.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(4):393-4 [9051252.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1346-56 [16219571.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4010-7 [19383914.001]
  • [Cites] Curr Opin Immunol. 2009 Apr;21(2):215-23 [19327974.001]
  • [Cites] Br J Haematol. 2008 Dec;143(5):641-53 [18950462.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] Cytotherapy. 2009;11(3):341-55 [19308771.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1907-14 [17611565.001]
  • [Cites] J Immunother. 2009 Feb-Mar;32(2):169-80 [19238016.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2643-52 [16352804.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3574-81 [18606875.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9 [15223016.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1873-80 [10657636.001]
  • [Cites] J Formos Med Assoc. 1998 Jan;97(1):55-8 [9481066.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5058-61 [17317850.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35 [17855649.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10995-1004 [17108138.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1353-66, x [11147227.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):483-93 [18026156.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] Blood. 2004 Feb 1;103(3):767-76 [12958064.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Sep;21(3):467-83 [18790450.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):339-47 [17572712.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1):1-30 [16399566.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1631-8 [19104080.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3447-54 [15753458.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):163-9 [15937507.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1819-28 [16932339.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1186-93 [9780338.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S18-S24 [18724292.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1394-400 [19041062.001]
  • [Cites] Immunogenetics. 2000 Feb;51(2):99-107 [10663572.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1924-32 [17505014.001]
  • [Cites] Nat Med. 2003 Mar;9(3):279-86 [12579196.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Curr Oncol Rep. 2004 Sep;6(5):339-47 [15291974.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1325-31 [16269610.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2009-16 [11877273.001]
  • [Cites] Annu Rev Med. 1999;50:369-86 [10073284.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3948-55 [7524753.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):473-81 [18176612.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3813-20 [15280199.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):64-75 [19100369.001]
  • (PMID = 19649982.001).
  • [ISSN] 2040-3445
  • [Journal-full-title] Current opinion in molecular therapeutics
  • [ISO-abbreviation] Curr. Opin. Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA095152; United States / NCI NIH HHS / CA / R01 CA138738; United States / NCI NIH HHS / CA / CA95152; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA138738; United States / NCI NIH HHS / CA / P01 CA059350; United States / NCI NIH HHS / CA / CA59350
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  • [Other-IDs] NLM/ NIHMS746468; NLM/ PMC4694559
  •  go-up   go-down


52. Seshadri T, Pintilie M, Kuruvilla J, Keating A, Tsang R, Zadeh S, Crump M: Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma; 2009 Mar;50(3):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
  • Autologous hematopoietic stem cell transplantation (AHCT) for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL) results in long-term disease-free survival in 40-50% of patients.
  • We analysed 372 patients with relapsed/refractory aggressive NHL who underwent AHCT from 1987 to 2006.
  • When compared with the general population, the relative-risk of acute myeloid leukemia and new solid tumor was 13.2 (p < 0.0001) and 2.3 (p = 0.0013).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Carmustine / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Incidence. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Retrospective Studies. Risk Factors. Salvage Therapy / methods. Transplantation, Autologous. Whole-Body Irradiation / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347727.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


53. Mustjoki S, Hernesniemi S, Rauhala A, Kähkönen M, Almqvist A, Lundán T, Porkka K: A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica; 2009 Oct;94(10):1469-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).
  • [MeSH-major] Genes, abl / genetics. Intracellular Signaling Peptides and Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cells, B-Lymphoid / physiology. Pyrimidines / therapeutic use. Thiazoles / therapeutic use. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Amino Acid Sequence. Dasatinib. Gene Fusion / genetics. Humans. Male. Molecular Sequence Data

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2005 Jul 1;389(Pt 1):127-35 [15850461.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2220-1 [17541395.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Genes Chromosomes Cancer. 2008 May;47(5):379-85 [18205209.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4849-52 [15713800.001]
  • [Cites] Blood. 2001 Jan 1;97(1):4-13 [11133737.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):274-82 [11170285.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Leukemia. 2009 Mar;23(3):627-9 [18987655.001]
  • (PMID = 19794096.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Pyrimidines; 0 / RCSD1 protein, human; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  • [Other-IDs] NLM/ PMC2754971
  •  go-up   go-down


54. Ishitsuka K, Katsuya H, Toyota T, Ishizu M, Kunami N, Fujita M, Sasaki H, Takamatsu Y, Uchiyama M, Fujikane H, Ogata K, Hara S, Tamura K: Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients. Int J Hematol; 2010 Dec;92(5):762-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients.
  • It is impossible to draw any definitive conclusion from this small study; however, IFN/AZT showed clear anti-ATL effects for refractory/relapsed ATL patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Zidovudine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] J Antimicrob Chemother. 1993 Mar;31(3):421-8 [8098029.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] J Clin Oncol. 2010 Sep 20;28(27):4177-83 [20585095.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):208-15 [11091203.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):453-9 [19064971.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):185-96 [18081707.001]
  • (PMID = 21080125.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Receptors, Interleukin-2; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


55. Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1092-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
  • The aim of this study was to determine the feasibility, efficacy and toxicity of the combined therapy consisting of cladribine (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in patients with refractory or relapsed non-Hodgkin's lymphoma (NHL).
  • Thirty six patients, 14 with mantle cell lymphoma (MCL), 10 with diffuse large B-cell lymphoma (DLBCL), 5 with follicular lymphoma (FL), 3 with small lymphocytic lymphoma (SLL), and 4 with T-cell lymphoma were enrolled to the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cladribine / adverse effects. Cladribine / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Feasibility Studies. Female. Humans. Male. Middle Aged. Mitoxantrone / adverse effects. Mitoxantrone / therapeutic use. Salvage Therapy / adverse effects. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; CMC protocol 2
  •  go-up   go-down


56. Yokoyama H, Yamamoto J, Tohmiya Y, Yamada MF, Ohguchi H, Ohnishi Y, Okitsu Y, Fukuhara N, Ohba-Ohtsuka R, Kohata K, Ishizawa K, Kameoka J, Harigae H: Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type. Leuk Lymphoma; 2010 Aug;51(8):1509-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type.
  • The prognosis of advanced extranodal NK/T cell lymphoma (ENKTL) is poor.
  • Allogeneic hematopoietic stem cell transplant (allo-HSCT) has been suggested to be a promising treatment for this disease, but its utility has yet to be established.
  • After induction chemotherapy, disease status at allo-HSCT was second CR in three patients and refractory in two patients.
  • [MeSH-major] Asparaginase / therapeutic use. Drug Resistance, Neoplasm. Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell / therapy. Natural Killer T-Cells / pathology. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cyclosporine / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Remission Induction. Retrospective Studies. Salvage Therapy. Survival Rate. Transplantation, Homologous. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496989.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


57. Ochenrider MG, Patterson DJ, Aboulafia DM: Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):144-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
  • Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of peripheral T-cell lymphoma.
  • He died 7 months after diagnosis from chemotherapy-refractory lymphoma.
  • [MeSH-major] Antibodies, Monoclonal. Crohn Disease / drug therapy. Liver Neoplasms / chemically induced. Lymphoma, T-Cell / chemically induced. Splenic Neoplasms / chemically induced
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adalimumab. Adolescent. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Azathioprine / therapeutic use. Fatal Outcome. Humans. Infliximab. Leukemia-Lymphoma, Adult T-Cell / chemically induced. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell, Peripheral / chemically induced. Lymphoma, T-Cell, Peripheral / drug therapy. Male. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371449.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; E7WED276I5 / 6-Mercaptopurine; FYS6T7F842 / Adalimumab; MRK240IY2L / Azathioprine
  • [Number-of-references] 24
  •  go-up   go-down


58. Bacher U, Schnittger S, Grüneisen A, Haferlach T, Kern W, Haferlach C: Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies. Cancer Genet Cytogenet; 2009 Jan 15;188(2):108-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To further describe structural anomalies involving the 1q21 and 1q32 breakpoints, we present four cases with an inverted dup(1)(q32q21): three in B-cell precursor acute lymphoblastic leukemia (ALL) and one in MDS of the subtype refractory cytopenia with multilineage dysplasia and ringed sideroblasts.
  • In one of the ALL cases, relapse during chemotherapy, 5 months from diagnosis, was accompanied by clonal evolution; in another ALL case, early relapse appeared 51 days after allogeneic stem cell transplantation.
  • [MeSH-minor] Adult. Aged. Chromosome Banding. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Trisomy

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19100515.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Robak T, Jamroziak K, Robak P: Current and emerging treatments for chronic lymphocytic leukaemia. Drugs; 2009;69(17):2415-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current and emerging treatments for chronic lymphocytic leukaemia.
  • Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia in Europe and North America.
  • In randomized trials, the combination of rituximab with fludarabine and cyclophosphamide (FC-R regimen) demonstrated higher rates of OR, CR and progression-free survival in patients with previously untreated and relapsed or refractory CLL than fludarabine plus cyclophosphamide (FC regimen).
  • Several reports have confirmed significant activity with alemtuzumab in relapsed or refractory CLL, as well as in previously untreated patients.
  • In recent years, a significant improvement in haematopoietic stem cell transplantation (HSCT) procedures in patients with high-risk CLL has been observed.
  • [MeSH-minor] Adult. Animals. Antibodies, Monoclonal, Humanized. Disease Models, Animal. Europe. Humans. Leukemia, Lymphocytic, Chronic, B-Cell. Male. Mice. North America. Rats

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Mar 15;99(6):2245-7 [11877305.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):573-8 [17906454.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] Mini Rev Med Chem. 2009 Jun;9(7):805-12 [19519505.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2412-7 [18067017.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2337-42 [16618945.001]
  • [Cites] Blood. 2008 Aug 15;112(4):975-80 [18411418.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):123-36 [18537755.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2107-14 [9179056.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2519-25 [18427150.001]
  • [Cites] Ther Clin Risk Manag. 2007 Oct;3(5):855-70 [18473009.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):151-3 [8611450.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1741-6 [17389337.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):473-9 [19117340.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7 [18040043.001]
  • [Cites] Leuk Res. 2010 Mar;34(3):284-8 [19646755.001]
  • [Cites] Ann Diagn Pathol. 2007 Oct;11(5):363-89 [17870025.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Mar;8(2):156-71 [18336199.001]
  • [Cites] Hematol J. 2004;5 Suppl 1:S31-7 [15079151.001]
  • [Cites] Haematologica. 2008 Mar;93(3):475-6 [18310545.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:390-7 [17124088.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):247-53 [17906297.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] Leukemia. 2004 Mar;18(3):409-14 [14712290.001]
  • [Cites] Leuk Lymphoma. 2009 Feb;50(2):171-8 [19197731.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] Br J Haematol. 2002 Sep;118(4):959-67 [12199773.001]
  • [Cites] Leuk Lymphoma. 1994 Mar;13(1-2):75-80 [8025525.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Curr Opin Mol Ther. 2008 Jun;10 (3):294-309 [18535937.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1216-23 [17470451.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):220-7 [15072613.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):78-84 [17161912.001]
  • [Cites] Am J Hematol. 2007 Dec;82(12):1063-70 [17654680.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2756-62 [18451242.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2333-43 [19052982.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2811-8 [17638850.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7024-31 [16145065.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2048-53 [18754025.001]
  • [Cites] Leukemia. 2004 Apr;18(4):747-55 [14973497.001]
  • [Cites] Eur J Cancer Care (Engl). 2004 Jul;13(3):279-87 [15196232.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5208-12 [19738118.001]
  • [Cites] Cell Mol Biol Lett. 2005;10(3):479-98 [16217558.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Feb;9(2):165-74 [19192955.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):1995-8 [18949622.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3421-8 [18451170.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] Cancer Treat Rev. 2007 Dec;33(8):710-28 [17904294.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4390-8 [15994148.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Leuk Res. 2004 May;28(5):429-42 [15068894.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Ann Hematol. 2003 Dec;82(12):759-65 [14551737.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):590-5 [17906457.001]
  • [Cites] Leukemia. 2004 Mar;18(3):484-90 [14749699.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6325-32 [16155015.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):361-7 [18202410.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] Bone Marrow Transplant. 2009 Nov;44(9):579-83 [19308041.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):1931-9 [17917961.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):425-32 [17762565.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55 [17671129.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1007-11 [12148879.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):27-36 [12270059.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] Br J Haematol. 2004 May;125(3):294-317 [15086411.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2583-91 [15197800.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5165-73 [16951235.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2906-16 [18591385.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2027-31 [14630811.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Leuk Res. 2005 Nov;29(11):1253-7 [15916806.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4378-84 [19652068.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8331-8 [16166310.001]
  • [Cites] Leukemia. 2007 Jan;21(1):12-7 [17109028.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6916-23 [16203783.001]
  • [Cites] Curr Med Chem. 2006;13(26):3165-89 [17168705.001]
  • [Cites] Haematologica. 2005 Jul;90(7):994-6 [15996945.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):369-78 [15650771.001]
  • [Cites] Blood. 1990 Apr 1;75(7):1422-5 [2180493.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):94-100 [19025975.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4176-81 [15930354.001]
  • [Cites] Br J Haematol. 2000 Feb;108(2):357-68 [10691866.001]
  • [Cites] Leuk Res. 2003 Oct;27(10):951-6 [12860016.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Jun;17(6):939-44 [18491994.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1278-84 [12663715.001]
  • [Cites] Blood. 2009 Jul 16;114(3):638-46 [19387007.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3413-20 [18451169.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Cancer Immunol Immunother. 2008 Nov;57(11):1705-10 [18663443.001]
  • [Cites] Br J Haematol. 1989 Nov;73(3):334-40 [2690923.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7697-702 [16186597.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):78-85 [19016731.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1207-10 [15858611.001]
  • [Cites] J Cell Biochem. 2004 Oct 15;93(3):629-38 [15378599.001]
  • [Cites] Blood. 2005 Jan 1;105(1):397-404 [15117764.001]
  • [Cites] Exp Hematol. 2008 May;36(5):568-76 [18346839.001]
  • [Cites] Anticancer Drugs. 2006 Jun;17(5):487-94 [16702804.001]
  • [Cites] Blood. 2009 Jan 8;113(2):299-305 [18931344.001]
  • [Cites] Leukemia. 2009 Apr;23 (4):686-97 [19092849.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3348-52 [16051743.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Cell. 2007 Mar 23;128(6):1173-86 [17382885.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1575-81 [16520464.001]
  • [Cites] IDrugs. 2006 Oct;9(10):712-22 [17016779.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):3-12 [16371014.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1015-27 [12040433.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]
  • [Cites] Br J Haematol. 2001 Aug;114(2):342-8 [11529853.001]
  • [Cites] Br J Haematol. 2009 Mar;144(6):818-31 [19183194.001]
  • [Cites] Ann Hematol. 2009 Mar;88(3):221-7 [18704419.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii60-2 [18456771.001]
  • [Cites] Oncogene. 2009 Sep 17;28(37):3261-73 [19581935.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2371 [19282461.001]
  • [Cites] Curr Med Chem. 2008;15(29):3036-51 [19075651.001]
  • [Cites] Blood. 2009 Oct 15;114(16):3382-91 [19605849.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1443-52 [18550857.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3994-4001 [19597025.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2723-9 [11023504.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):53-8 [19147079.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):155-61 [18172266.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7801-9 [16885384.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2846-52 [15087402.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):348-9 [18202406.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):527-36 [9030781.001]
  • [Cites] Hematol J. 2002;3(5):244-50 [12391542.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:93-6 [27463487.001]
  • [Cites] Bioorg Med Chem. 2000 Aug;8(8):1841-60 [11003129.001]
  • [Cites] Leuk Lymphoma. 2009 Dec;50(12):1958-63 [19860603.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):498-503 [19075274.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):976-84 [12472576.001]
  • [Cites] Br J Haematol. 2008 Dec;143(5):698-706 [19062342.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5809-16 [17020988.001]
  • [Cites] Blood. 2000 Jul 15;96(2):393-7 [10887097.001]
  • [Cites] Hematol Oncol. 2009 Jun;27(2):53-60 [19358149.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1621-7 [15990861.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):770-6 [2016618.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1260-7 [15051774.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Leuk Res. 2007 Feb;31(2):253-6 [16815546.001]
  • [Cites] Drugs Aging. 2005;22(12):983-1012 [16363884.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):433-6 [3065739.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1093-101 [15071604.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Apr;18(4):491-500 [19335277.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):205-19 [15101704.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):861-8 [10340906.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1029-33 [15830011.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2291-8 [17514743.001]
  • [Cites] Curr Med Chem. 2009;16(18):2212-34 [19519388.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3819-29 [15809448.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):613-26 [18687642.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5350-8 [18292288.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213 [12162702.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1594-602 [18032710.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Jul;8(7):1033-51 [18588450.001]
  • [Cites] Curr Opin Investig Drugs. 2009 Jun;10(6):588-96 [19513948.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2824-36 [19402170.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4484-91 [15692065.001]
  • [Cites] Ann Intern Med. 1996 Feb 1;124(3):311-5 [8554226.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):107-13 [17635235.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3644-53 [17530018.001]
  • [Cites] Clin Pharmacokinet. 2004;43(2):83-95 [14748618.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1816-9 [18039954.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4578-84 [19704063.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):377-89 [16793209.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):373-80 [19117034.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1510-6 [11587207.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):95-8 [19016732.001]
  • [Cites] Semin Hematol. 2004 Jul;41(3):224-33 [15269882.001]
  • [Cites] Blood. 2006 Jul 15;108(2):473-9 [16551966.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1165-71 [9694704.001]
  • [Cites] Br J Pharmacol. 2006 Aug;148(8):1116-23 [16847437.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] Med Sci Monit. 2005 Oct;11(10):PI71-9 [16192912.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 19911856.001).
  • [ISSN] 1179-1950
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / lumiliximab; 3A189DH42V / alemtuzumab
  •  go-up   go-down


60. Dearden CE: T-cell prolymphocytic leukemia. Med Oncol; 2006;23(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive post-thymic malignancy with poor response to conventional treatment and short survival.
  • It can readily be distinguished from other T-cell leukemias on the basis of the distinctive morphology, immunophenotype, and cytogenetics.
  • Consistent chromosomal translocations involving the T-cell receptor gene and one of two protooncogenes (TCL-1 and MTCP-1) are seen in the majority of cases and are likely to be involved in the pathogenesis of the disorder.
  • In relapsed/refractory patients overall and complete response rates have been seen in up to 76% and 60%, respectively.
  • However, relapse is inevitable and strategies using both autologous and allogeneic stem cell transplantation are currently being explored.
  • [MeSH-major] Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Humans. Immunophenotyping. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1996 Oct 1;10(19):2411-22 [8843194.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2331-4 [12613520.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Ann Hematol. 2001 Dec;80(12):749-51 [11797117.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Science. 1985 Mar 1;227(4690):1044-7 [3919442.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1923-7 [8634440.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1305-11 [9264385.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):248-54 [11391795.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5452-6 [9407948.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):336-41 [11241786.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2475-83 [8361760.001]
  • [Cites] Blood. 1998 May 15;91(10):3920-6 [9573030.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):921-7 [8703826.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] Lancet. 1973 Aug 4;2(7823):232-4 [4124423.001]
  • (PMID = 16645226.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


61. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood; 2007 Jun 15;109(12):5136-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
  • We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine.
  • All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission.
  • Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1984 Sep;74(3):951-5 [6332120.001]
  • [Cites] Blood. 1983 Apr;61(4):660-6 [6600944.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3646-50 [2410098.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6498-502 [2819707.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Transplantation. 1991 Oct;52(4):634-40 [1926342.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3352-6 [7614470.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):70-82 [9045306.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):896-903 [9217194.001]
  • [Cites] Adv Exp Med Biol. 1984;165 Pt B:309-14 [6609537.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1216-30 [10506707.001]
  • [Cites] Biochemistry. 1964 Jan;3:15-8 [14114497.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):995-1003 [10694549.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Biochemistry. 1981 Jun 9;20(12):3615-21 [6789872.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1008-14 [3971358.001]
  • (PMID = 17344466.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Other-IDs] NLM/ PMC1941786
  •  go-up   go-down


62. Kaygusuz I, Toptas T, Guven A, Firatli-Tuglular T, Tecimer T, Bayik M: Precursor B cell lymphoblastic lymphoma presenting as a solitary bone tumor: a case report and review of the literature. Int J Hematol; 2010 Dec;92(5):757-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B cell lymphoblastic lymphoma presenting as a solitary bone tumor: a case report and review of the literature.
  • Precursor B cell lymphoblastic lymphoma (B-LBL) is quite uncommon and it usually manifests as an extranodal disease.
  • Here, we report a case of precursor B-LBL presenting with solitary bone tumor and a review of a total of seven adult patients reported previously in the literature.
  • Unlike previous reports except one case, our patient underwent allogeneic stem cell transplantation (allo-SCT) due to refractory disease.
  • B-LBL has an aggressive clinical course in adult patients and allo-SCT may be the best treatment option.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Anti-Inflammatory Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Prednisone / administration & dosage. Transplantation, Homologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 Feb 1;73(3):706-10 [7507799.001]
  • [Cites] Am J Clin Pathol. 1988 Nov;90(5):602-5 [3052024.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1480-90 [11075849.001]
  • [Cites] Int J Hematol. 2000 Dec;72(4):504-6 [11197221.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):795-804 [9669342.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):868-75 [11392884.001]
  • [Cites] Am J Clin Pathol. 1999 Dec;112(6):836-43 [10587707.001]
  • [Cites] Arch Pathol Lab Med. 2009 Nov;133(11):1868-71 [19886726.001]
  • (PMID = 21080126.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


63. Sigalas P, Tourvas AD, Moulakakis A, Pangalis G, Kontopidou F: Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature. Leuk Res; 2009 Jul;33(7):e61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Humans. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157550.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 23
  •  go-up   go-down


64. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M: Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma; 2008 Jul;49(7):1329-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.
  • Primary mediastinal large B-cell lymphoma (PMLCL) is an aggressive non-Hodgkin lymphoma with distinct clinical and gene expression profiles.
  • Outcomes of salvage chemotherapy and autologous stem cell transplantation (ASCT) for relapsed or refractory disease (RR) have not been well characterised.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Mediastinal Neoplasms / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Treatment Outcome


65. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV: A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood; 2007 Mar 15;109(6):2571-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As butyrate has been shown to sensitize EBV(+) lymphoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refractory EBV(+) lymphoid malignancies to evaluate the drug combination for toxicity, pharmacokinetics, and clinical responses.
  • The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to have significant biologic activity in vivo in EBV(+) lymphoid malignancies which are refractory to other regimens.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1970 Nov 15;6(3):450-62 [4321018.001]
  • [Cites] Nature. 1977 Aug 4;268(5619):462-4 [268489.001]
  • [Cites] J Biol Chem. 1978 May 25;253(10):3364-6 [649576.001]
  • [Cites] Cancer. 1980 Mar 15;45(5 Suppl):1185-92 [7357511.001]
  • [Cites] J Virol. 1980 May;34(2):560-8 [6246281.001]
  • [Cites] Cancer. 1983 Jan 1;51(1):9-14 [6571794.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 May;80(9):2767-70 [6302704.001]
  • [Cites] Ann Surg. 1983 Sep;198(3):356-69 [6311121.001]
  • [Cites] FEBS Lett. 1984 Jan 30;166(2):326-30 [6319196.001]
  • [Cites] J Virol. 1984 Apr;50(1):50-5 [6321799.001]
  • [Cites] Arch Virol. 1984;81(3-4):223-37 [6089703.001]
  • [Cites] Biochemistry. 1985 Apr 9;24(8):2027-33 [2990549.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] EMBO J. 1986 Aug;5(8):1959-66 [3019675.001]
  • [Cites] J Biol Chem. 1987 Jan 25;262(3):1092-7 [3805014.001]
  • [Cites] Ann Intern Med. 1987 Sep;107(3):348-50 [3039887.001]
  • [Cites] Am J Pathol. 1987 Oct;129(1):86-91 [2821817.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Sep;23(9):1283-7 [3678322.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Oct 29;148(2):694-700 [3689367.001]
  • [Cites] JAMA. 1988 Jan 15;259(3):384-8 [2826830.001]
  • [Cites] N Engl J Med. 1988 Mar 24;318(12):733-41 [2831453.001]
  • [Cites] Blood. 1988 Aug;72(2):520-9 [2840986.001]
  • [Cites] J Virol. 1988 Oct;62(10):3892-5 [2843685.001]
  • [Cites] Am J Med. 1989 Feb;86(2):241-4 [2536518.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):502-6 [2536894.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):128-30 [1967431.001]
  • [Cites] J Cell Physiol. 1990 Oct;145(1):46-52 [1976640.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):801-4 [2172169.001]
  • [Cites] Hematol Oncol. 1990 Sep-Oct;8(5):271-81 [1979042.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Nov;42(11):2923-31 [9797227.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1790-7 [10068649.001]
  • [Cites] Bone Marrow Transplant. 1999 Feb;23(3):251-8 [10084256.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1349-50 [10451431.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1376-81 [10451442.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2208-16 [10498590.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] J Cell Physiol. 2005 Jan;202(1):87-99 [15389542.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Mar;6(5):417-9 [16640822.001]
  • [Cites] Blood Cells Mol Dis. 2007 Jan-Feb;38(1):57-65 [17161633.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4055-63 [11110673.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Jul;39(7):1599-602 [7492112.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):21-5 [10561014.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):59-63 [10608506.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:113-6 [10707791.001]
  • [Cites] Int J Hematol. 2000 Feb;71(2):108-17 [10745621.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Apr;34(1):27-53 [10781747.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1849-51 [11078764.001]
  • [Cites] Transpl Infect Dis. 2001 Jun;3(2):108-18 [11395969.001]
  • [Cites] Transpl Infect Dis. 2001 Sep;3(3):177-85 [11493400.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3047-55 [11595694.001]
  • [Cites] Yonsei Med J. 2002 Apr;43(2):175-82 [11971211.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):759-64 [12118114.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4640-8 [12393583.001]
  • [Cites] Virology. 2002 Nov 25;303(2):345-63 [12490396.001]
  • [Cites] Biochem J. 1990 Dec 1;272(2):541-4 [2268282.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Eur J Haematol. 1991 Feb;46(2):93-100 [1995327.001]
  • [Cites] Int J Cancer. 1991 May 10;48(2):291-6 [1708367.001]
  • [Cites] Int J Cancer. 1991 May 30;48(3):443-9 [2040538.001]
  • [Cites] Neurochem Res. 1992 Apr;17(4):315-20 [1381055.001]
  • [Cites] Leukemia. 1992 Sep;6(9):869-74 [1325580.001]
  • [Cites] N Engl J Med. 1993 Jan 14;328(2):81-6 [7677966.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2102-9 [8386027.001]
  • [Cites] Int J Cancer. 1993 Apr 1;53(6):898-901 [7682538.001]
  • [Cites] Blood. 1993 May 15;81(10):2688-95 [8387835.001]
  • [Cites] Histopathology. 1993 Dec;23(6):509-18 [8314234.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1612-8 [8123852.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2932-8 [7773944.001]
  • [Cites] Transplant Proc. 1995 Oct;27(5 Suppl 1):58-9 [7482823.001]
  • [Cites] Ann Oncol. 1996;7 Suppl 4:11-7 [8836403.001]
  • [Cites] Semin Cancer Biol. 1996 Aug;7(4):175-82 [8946601.001]
  • [Cites] Semin Cancer Biol. 1996 Aug;7(4):191-6 [8946603.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):2-7 [9044504.001]
  • [Cites] Br J Haematol. 1997 Aug;98(2):485-7 [9266955.001]
  • [Cites] Bone Marrow Transplant. 1997 Aug;20(4):337-40 [9285550.001]
  • [Cites] Curr Opin Hematol. 1995 Mar;2(2):109-17 [9371980.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):53-7 [9500191.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(11):1155-8 [9645581.001]
  • [Cites] Cell Growth Differ. 1998 Jun;9(6):465-74 [9663465.001]
  • [Cites] Blood Cells Mol Dis. 1998 Jun;24(2):114-23 [9628848.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 May;51(5):439-44 [12736763.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):175-84 [12876666.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4636-43 [14996704.001]
  • [Cites] Curr Hematol Rep. 2004 Jul;3(4):227-9 [15217551.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1447-57 [15467034.001]
  • [Cites] J Virol. 2004 Nov;78(22):12140-6 [15507600.001]
  • [Cites] Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101 [5242134.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • (PMID = 17119113.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA085687; United States / NCI NIH HHS / CA / CA85687; United States / FDA HHS / FD / FD-R-001532
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Butyrates; 94ZLA3W45F / Arginine; IK8S1P79MU / arginine butyrate; P9G3CKZ4P5 / Ganciclovir
  • [Other-IDs] NLM/ PMC1852196
  •  go-up   go-down


66. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M, Société Française de Greffe de Moëlle et de Thérapie Cellulaire: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol; 2008 May 10;26(14):2264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
  • PURPOSE: Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's lymphomas (NHLs) in adults.
  • ATCLs show a worse prognosis than B-cell lymphomas.
  • PATIENTS AND METHODS: On behalf of the Société Française de Greffe de Moëlle et de Thérapie Cellulaire, we conducted a retrospective analysis including 77 ATCL patients who underwent allogeneic stem-cell transplantation (alloSCT).
  • RESULTS: The different diagnosis included anaplastic large-cell lymphoma (ALCL; n = 27), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; n = 27), angioimmunoblastic T-cell lymphoma (AITL; n = 11), hepatosplenic gamma/delta lymphoma (HSL; n = 3), T-cell granular lymphocytic leukemia (T-GLL; n = 1), nasal natural killer (NK)/T-cell lymphoma (nasal-NK/L; n = 3) or non-nasal NK/T-cell lymphoma (non-nasal-NK/L; n = 2), enteropathy-type T-cell (n = 1), and human T-lymphotropic virus (HTLV)-1 lymphoma (n = 2).
  • In multivariate analysis, chemoresistant disease (stable, refractory, or progressing disease) at the time of alloSCT and the occurrence of severe grade 3 to 4 acute graft-versus-host disease (aGVHD) were the strongest adverse prognostic factors for OS (P = .03 and .03, respectively).
  • [MeSH-major] Graft vs Tumor Effect / immunology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Child. Disease-Free Survival. Female. Graft vs Host Disease / immunology. Humans. Male. Middle Aged. Retrospective Studies. Transplantation Conditioning. Transplantation, Homologous / immunology


67. Scupoli MT, Donadelli M, Cioffi F, Rossi M, Perbellini O, Malpeli G, Corbioli S, Vinante F, Krampera M, Palmieri M, Scarpa A, Ariola C, Foà R, Pizzolo G: Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica; 2008 Apr;93(4):524-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways.
  • BACKGROUND: Cytokines released in the bone marrow and thymic microenvironments play a key role in the growth of T-cell acute lymphoblastic leukemia.
  • Among such cytokines, interleukin-8 is highly expressed in T-cell acute lymphoblastic leukemia cells refractory to chemotherapy.
  • In this study we explored whether bone marrow stromal cells can regulate IL-8 expression in T-cell acute lymphoblastic leukemia and investigated the role of the stromal CXCL12 chemokine in this event.
  • DESIGN AND METHODS: We analyzed the expression of interleukin-8 in primary cells from ten adult patients with T-cell acute lymphoblastic leukemia when these cells were cultured with bone marrow stromal cells or stimulated with exogenous CXCL12.
  • Nuclear factor-kappaB and JNK/AP-1 activation was investigated by using specific inhibitors of these pathways, immunoblotting, electrophoretic mobility-shift assay and cell transfection assays.
  • RESULTS: Bone marrow stromal cells upregulated interleukin-8 mRNA in T-cell acute lymphoblastic leukemia cells through the activity of CXCR4, the CXCL12 receptor, as assessed by the use of neutralizing antibodies.
  • Exogenous CXCL12 induced a significant increase in the production of IL-8 mRNA and protein in all T-cell acute lymphoblastic leukemia cases.
  • CONCLUSIONS: Interleukin-8 is physiologically regulated by the CXCL12/CXCR4 axis and the nuclear factor-kappaB and JNK/AP-1 pathways are required for interleukin-8 expression in T-cell acute lymphoblastic leukemia.
  • We propose that, by upregulating interleukin-8, the bone marrow microenvironment and the CXCL12/CXCR4 axis may play a role in the pathogenesis of T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Bone Marrow Cells / metabolism. Chemokine CXCL12 / physiology. Gene Expression Regulation, Leukemic / physiology. Interleukin-8 / biosynthesis. JNK Mitogen-Activated Protein Kinases / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism. NF-kappa B / physiology. Neoplasm Proteins / physiology. Receptors, CXCR4 / physiology. Stromal Cells / metabolism. Transcription Factor AP-1 / physiology. Up-Regulation / physiology
  • [MeSH-minor] Adult. Clinical Trials as Topic / statistics & numerical data. Humans. Jurkat Cells / drug effects. Jurkat Cells / metabolism. Multicenter Studies as Topic / statistics & numerical data. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Recombinant Fusion Proteins / physiology. Transfection

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Apr;93(4):493-7 [18379008.001]
  • (PMID = 18322253.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Interleukin-8; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, CXCR4; 0 / Recombinant Fusion Proteins; 0 / Transcription Factor AP-1; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


68. Ogata S, Hamada N, Maeyama T, Takayama K, Inoue H, Nakanishi Y: [A case of interstitial pneumonia with smoldering adult T-cell leukemia]. Nihon Kokyuki Gakkai Zasshi; 2010 Apr;48(4):293-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of interstitial pneumonia with smoldering adult T-cell leukemia].
  • Inverse PCR for HTLV-1 clonality of the peripheral blood revealed a polyclonal pattern, and she was given a diagnosis of smoldering adult T-cell leukemia.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / complications. Leukemia-Lymphoma, Adult T-Cell / complications. Lung Diseases, Interstitial / etiology

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432970.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM: High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant; 2005 Jan;11(1):13-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
  • Over a 10-year period (January 1993 to October 2002), 101 relapsed or refractory non-Hodgkin lymphoma patients were treated at our center with high-dose chemotherapy and autologous transplantation.
  • Thirty-two patients had indolent (low-grade), 42 had aggressive (intermediate-grade), and 27 had very aggressive (high-grade) non-Hodgkin lymphoma.
  • Thirty-six patients had primary refractory disease, 20 had a chemoresistant relapse, 35 patients had a chemosensitive relapse, and 10 patients were "initial high risk" patients.
  • Most patients (n = 93) received mobilized peripheral blood stem cells (median CD34 + cell dose, 6.7 x 10 6 /kg).
  • Four patients (4%) died within 30 days of stem cell infusion (1 pulmonary embolism, 2 septicemias with multiorgan failure, and 1 progressive lymphoma).
  • Three cases (3%) of secondary acute myelogenous leukemia occurred.
  • BEP with or without IFR is a highly effective and well-tolerated regimen in the relapsed/refractory lymphoma setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasms, Second Primary / etiology. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / mortality. Salvage Therapy / methods. Salvage Therapy / mortality. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625540.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


70. Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, McSweeney P, Niederwieser D, Bruno B, Storb R, Maloney DG: Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol; 2010 Jul;150(2):170-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.
  • Patients with T-cell and natural killer-cell lymphomas have poor outcomes.
  • This study examined the role of allogeneic haematopoietic cell transplantation (allo-HCT) after nonmyeloablative conditioning in this setting.
  • Seventeen patients with T-cell lymphoma or NK-cell lymphoma, including three patients in first complete remission, received allo-HCT after 2 Gy total-body irradiation and fludarabine.
  • The median number of prior therapies was 3 (range, 1-7), six patients (35%) had failed prior autologous HCT, and five patients (29%) had refractory disease at the time of allograft.
  • Allo-HCT after nonmyeloablative conditioning is a promising salvage option for selected patients with T-cell and NK-cell lymphomas.
  • These results suggest that graft-versus-T-cell lymphoma activity is responsible for long-term disease control.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Oct;13(5):1091-112, viii-ix [10553263.001]
  • [Cites] Eur J Haematol. 2007 Apr;78(4):290-6 [17378891.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3447-54 [12855572.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):441-6 [15160904.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Blood. 2004 Aug 15;104(4):961-8 [15113759.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1550-8 [15150081.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Blood. 1990 Jul 15;76(2):424-31 [1973361.001]
  • [Cites] Blood. 1991 Feb 1;77(3):649-53 [1991174.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1050-5 [8049425.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):859-63 [9404927.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3515-20 [9808542.001]
  • [Cites] Bone Marrow Transplant. 1999 Feb;23(4):329-33 [10100576.001]
  • [Cites] Anat Pathol. 1998;3:77-145 [10389582.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):154-61 [10520036.001]
  • [Cites] Leukemia. 2005 May;19(5):829-34 [15744352.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):218-24 [18182664.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3390-400 [11369628.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] Haematologica. 2002 Dec;87(12):1343-5 [12495907.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):857-66 [12873880.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2021-30 [12791654.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3819-29 [15809448.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Leukemia. 2006 Jan;20(1):128-35 [16270037.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):965-72 [16920563.001]
  • [Cites] Int J Hematol. 2007 Jan;85(1):18-25 [17261497.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • (PMID = 20507311.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-22; United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA92058; United States / NCI NIH HHS / CA / K23 CA092058; United States / NCI NIH HHS / CA / P01 CA049605-22; United States / NCI NIH HHS / CA / CA49605; United States / NHLBI NIH HHS / HL / R00 HL088021; United States / NCI NIH HHS / CA / K23 CA092058-05; United States / NCI NIH HHS / CA / P01 CA018029-36; United States / NHLBI NIH HHS / HL / HL088021-02; United States / NCI NIH HHS / CA / CA15704; United States / NHLBI NIH HHS / HL / K99 HL088021-02; United States / NCI NIH HHS / CA / P01 CA078902-13; United States / NCI NIH HHS / CA / CA092058-05; United States / NCI NIH HHS / CA / P01 CA078902; United States / NHLBI NIH HHS / HL / K99 HL088021; United States / NCI NIH HHS / CA / P01 CA049605; United States / NHLBI NIH HHS / HL / HL088021; United States / NCI NIH HHS / CA / P30 CA015704-37; United States / NCI NIH HHS / CA / CA078902-13
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS212466; NLM/ PMC2995443
  •  go-up   go-down


71. Bruno JJ, Canada TW: Possible pentostatin-induced symptomatic hyponatremia. Pharmacotherapy; 2007 Jan;27(1):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pentostatin is an adenosine deaminase inhibitor used in the treatment of hairy cell leukemia and T-cell lymphomas.
  • A 27-year-old man with refractory cutaneous T-cell lymphoma developed severe hyponatremia 3 days after completing his first cycle of pentostatin therapy.
  • [MeSH-minor] Adult. Humans. Lymphoma, T-Cell / drug therapy. Male

  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192171.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 395575MZO7 / Pentostatin
  •  go-up   go-down


72. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K: Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci; 2008 May;99(5):1016-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
  • Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are rare, and their standard therapy has not been established.
  • Patients with stage IV, relapsed or refractory diseases have a dismal prognosis, with survival measured in months only.
  • Eligible patients had newly diagnosed stage IV, relapsed or refractory diseases after first-line chemotherapy, were 15-69 years of age, and had satisfactory performance scores (0-2).
  • At level 1, six patients with extranodal NK/T-cell lymphoma, nasal type, were enrolled.
  • Their disease status was newly diagnosed stage IV (n = 3), first relapse (n = 2), and primary refractory (n = 1).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphoid / drug therapy. Lymphoma, Extranodal NK-T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Asparaginase / administration & dosage. Asparaginase / therapeutic use. Dexamethasone / administration & dosage. Dexamethasone / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Humans. Ifosfamide / administration & dosage. Ifosfamide / therapeutic use. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294294.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


73. Styczyński J, Haus O: [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults]. Postepy Hig Med Dosw (Online); 2006;60:527-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults].
  • In spite of continuous progress in the therapy of acute leukemia, relapses still occur frequently both in children and adults.
  • The presence of cytogenetic aberrations in leukemic cells at presentation is an important prognostic factor in acute leukemia.
  • The translocation t(9;22) and the 11q23/MLL rearrangement are related to poor prognosis, while hyperdiploidy >50 chromosomes and the translocation t(12;21) are indicators of good prognosis in acute lymphoblastic leukemia (ALL).
  • In acute myeloid leukemia (AML), t(8;21), t(15;17), and inv(16) indicate good prognosis, whereas 5/5q-, 7/7q-, and complex karyotype indicate poor prognosis.
  • Knowledge on the karyotype-related drug resistance profile might enable the use of targeted therapy in resistant/refractory acute leukemia both in children and adults.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060894.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins
  • [Number-of-references] 74
  •  go-up   go-down


74. Inoue H, Matsushita K, Arima N, Hamada H, Uozumi K, Ozaki A, Akimoto M, Kawada H, Kukita T, Yoshimitsu M, Matsumoto T, Tei C: High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia. Leuk Lymphoma; 2008 Feb;49(2):315-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia.
  • We examined human T-lymphotropic virus type I (HTLV-I) infection among patients with myelodysplastic syndrome (MDS), refractory anemia with excess of blasts (RAEB)/RAEB in transformation (RAEBt) and acute myelogenous leukemia (AML).
  • As a reference, we examined 92 patients with refractory anemia (RA) and 405 patients with cardiovascular diseases (CVD).
  • Seven AML patients with HTLV-I infection had M3 acute promyelocytic leukemia (APL).
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / virology. HTLV-I Infections / epidemiology. Leukemia, Promyelocytic, Acute / virology. Myelodysplastic Syndromes / virology
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic. Female. Humans. Male. Middle Aged. Platelet Count. Prevalence. Survival Rate


75. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A: Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol; 2008 Jul;19(7):1312-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
  • BACKGROUND: The purpose of this study was to assess prognostic factors and outcome of patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose chemotherapy and autologous stem-cell transplant (ASCT).
  • Demography at ASCT was 61% stage IV, median age 31 years (18-69), median prior treatment (tx) regimens 3 (2-7), median Hasenclever index 3 (0-6); 150 patients had responding disease [54 complete remission (CR), 96 partial remission (PR)], and 45 patients had untested relapse/refractory disease.
  • Twenty (10%) patients developed second cancer (seven secondary acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS)).
  • CONCLUSION: These data provide the longest follow-up reported for patients receiving ASCT for relapsed/refractory HL.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356139.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


76. Mone A, Puhalla S, Whitman S, Baiocchi RA, Cruz J, Vukosavljevic T, Banks A, Eisenbeis CF, Byrd JC, Caligiuri MA, Porcu P: Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. Blood; 2005 Nov 15;106(10):3380-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.
  • Adult T-cell leukemia (ATL) is a highly chemoresistant and usually fatal T-cell malignancy due to the human T-cell lymphotropic virus-1 (HTLV-1).
  • A patient with refractory chronic ATL in transformation achieved longer than a 1-year complete hematologic response following 12 weeks of outpatient subcutaneous alemtuzumab.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6948-58 [10602469.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):290-3 [10846838.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1069-85 [12040438.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Int J Hematol. 2002 Jul;76(1):91-3 [12138903.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):452-3 [12167696.001]
  • [Cites] Cytotherapy. 2001;3(3):137-43 [12171721.001]
  • [Cites] Med Oncol. 2002;19 Suppl:S27-32 [12180489.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Clin Lab Haematol. 2003 Apr;25(2):111-7 [12641615.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4267-72 [12543862.001]
  • [Cites] Leuk Lymphoma. 2003 Apr;44(4):611-8 [12769337.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6453-7 [14559836.001]
  • [Cites] Leukemia. 2004 Jan;18(1):167-9 [14603340.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):391-9 [14729650.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1846-54 [14630799.001]
  • [Cites] Blood. 2004 May 1;103(9):3278-81 [14726385.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2852-9 [15353320.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Aug;19(4):391-8 [15453953.001]
  • [Cites] J Immunol. 1985 May;134(5):3056-61 [3980990.001]
  • [Cites] Blood. 2005 Jan 1;105(1):289-91 [15217834.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 1;16(7):665-75 [10791877.001]
  • (PMID = 16076875.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA10215-02; United States / NCI NIH HHS / CA / P01 CA95426; United States / NCI NIH HHS / CA / T32 CA009338
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 0 / Interferon-alpha; 0 / Tumor Suppressor Protein p53; 3A189DH42V / alemtuzumab; 4B9XT59T7S / Zidovudine
  • [Other-IDs] NLM/ PMC1895052
  •  go-up   go-down


77. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res; 2006 Aug 1;12(15):4628-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
  • PURPOSE: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines.
  • EXPERIMENTAL DESIGN: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m(2)): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients).
  • [MeSH-major] Enzyme Inhibitors / administration & dosage. Histone Deacetylase Inhibitors. Hydroxamic Acids / administration & dosage. Leukemia, Myeloid / drug therapy. Myelodysplastic Syndromes / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Biomarkers, Tumor / antagonists & inhibitors. Biomarkers, Tumor / metabolism. Cell Proliferation / drug effects. Cinnamates / administration & dosage. Cinnamates / adverse effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Histones / drug effects. Histones / metabolism. Humans. Indoles. Injections, Intravenous. Maximum Tolerated Dose. Middle Aged. Predictive Value of Tests. Structure-Activity Relationship. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899611.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cinnamates; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Hydroxamic Acids; 0 / Indoles; 9647FM7Y3Z / panobinostat
  •  go-up   go-down


78. Fujiwara H, Kawada H, Matsushita K, Hamada H, Ozaki A, Inoue H, Yoshimitsu M, Kukita T, Arimura K, Ohtsubo H, Uozumi K, Arima N, Tei C: Case of a patient with progressive adult T-cell leukemia/lymphoma treated successfully by reduced-intensity conditioning stem cell transplantation from an HLA-incompatible related donor. Int J Hematol; 2005 Nov;82(4):357-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of a patient with progressive adult T-cell leukemia/lymphoma treated successfully by reduced-intensity conditioning stem cell transplantation from an HLA-incompatible related donor.
  • A 61-year-old man with progressive adult T-cell leukemia/lymphoma (ATLL) successfully received reduced-intensity conditioning stem cell transplantation (RIST) without T-cell depletion (TCD) from his HLA-incompatible son, who had negative results for human T-lymphotropic virus type 1 (HTLV-1) (1-locus, 1-allele mismatch in the graft-versus-host [GVH] direction; 2-loci, 1-allele mismatch in the host-versus-graft direction).
  • On approximately day 50 the patient started to experience steroid-refractory skin GVHD (grade IV), which was successfully managed with basiliximab (anti-CD25 monoclonal antibody) and mycophenolate mofetil (MMF).
  • In addition, basiliximab combined with MMF may be effective for the treatment of steroid-refractory skin GVHD without deteriorating the graft-versus-ATL effect.
  • [MeSH-major] Histocompatibility Testing. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Hematol. 2003 Nov;31(11):1019-25 [14585364.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3120-6 [11595704.001]
  • [Cites] J Immunol Methods. 2003 Apr 1;275(1-2):133-6 [12667677.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [6326131.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):193-206 [14531901.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jul;34(7):369-78 [15342663.001]
  • [Cites] Exp Hematol. 2002 Apr;30(4):340-5 [11937269.001]
  • [Cites] Int J Hematol. 2005 Jan;81(1):13-7 [15717682.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1):4-21 [14970932.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):437-43 [15254742.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12 ):899-903 [12476283.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6977-84 [11156399.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):533-40 [10953974.001]
  • [Cites] Virology. 1997 Oct 27;237(2):209-16 [9356333.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3821-8 [15280193.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):391-9 [14729650.001]
  • [Cites] Leukemia. 2004 Jan;18(1):167-9 [14603340.001]
  • [Cites] Curr Opin Oncol. 1995 Mar;7(2):115-21 [7756375.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):257-67 [15551352.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Clin Exp Immunol. 2003 Dec;134(3):426-30 [14632747.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Curr Opin Hematol. 2004 Nov;11(6):386-91 [15548992.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):777-86 [15009066.001]
  • [Cites] Leukemia. 2005 May;19(5):829-34 [15744352.001]
  • (PMID = 16298831.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


79. DeAngelo DJ: Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am; 2009 Oct;23(5):1121-35, vii-viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
  • Nelarabine has significant activity in patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL).
  • [MeSH-major] Arabinonucleosides / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Humans. Salvage Therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825456.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 34
  •  go-up   go-down


80. Roecker AM, Stockert A, Kisor DF: Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol; 2010 Dec 01;4:133-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine in the treatment of refractory T-cell malignancies.
  • Nelarabine is a nucleoside analog indicated for the treatment of adult and pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that is refractory or has relapsed after treatment with at least two chemotherapy regimens.
  • After being first synthesized in the late 1970s and receiving FDA approval in 2005, the appropriate use of nelarabine for refractory hematologic malignancies is still being elucidated.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151585.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999959
  • [Keywords] NOTNLM ; Arranon / Atriance / T-cell / leukemia / lymphoma / nelarabine
  •  go-up   go-down


81. Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD, Cancer and Leukemia Group B: Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma; 2007 Jan;48(1):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
  • CALGB Protocol 59901 was a Phase II study of nelarabine in patients with systemically untreated cutaneous T-cell lymphoma (CTCL) or refractory/relapsed systemic T-cell lymphoma (STCL).
  • Due to lack of efficacy and excessive toxicity, nelarabine is not recommended as monotherapy in adult patients with CTCL and STCL at this dose schedule.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prodrugs / adverse effects. Prodrugs / therapeutic use. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Jan;48(1):1-2 [17325839.001]
  • (PMID = 17325852.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Prodrugs; 60158CV180 / nelarabine
  •  go-up   go-down


82. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A, Hx-CD20-406 Study Investigators: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol; 2010 Apr 01;28(10):1749-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
  • PURPOSE: New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemtuzumab treatment; these groups have poor outcomes with available salvage regimens.
  • CONCLUSION: Ofatumumab is an active, well-tolerated treatment providing clear clinical improvements for fludarabine-refractory patients with very poor-prognosis CLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2010 Aug 1;28(22):3670
  • [Cites] J Immunol. 2006 Jul 1;177(1):362-71 [16785532.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] J Immunol. 2009 Jul 1;183(1):749-58 [19535640.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):1931-9 [17917961.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2367-9 [19052987.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]
  • [Cites] Eur J Haematol. 2002 Sep;69(3):129-34 [12406005.001]
  • [Cites] Blood. 2009 May 14;113(20):4834-40 [19264918.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2971-9 [15738539.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2033-9 [11932906.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3257-63 [9779699.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2408-16 [17054106.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):460-2 [19266387.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):822-32 [18566448.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 20194866.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00349349
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; M95KG522R0 / ofatumumab; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC4979101
  •  go-up   go-down


83. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG: Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant; 2008 Jul;14(7):741-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
  • The peripheral T cell lymphomas (PTCL) carry a worse prognosis compared to B cell non-Hodgkin lymphoma.
  • There is no uniform standard therapy for PTCL, and autologous hematopoietic cell transplant (AHCT) is often offered as consolidation in first remission or at relapse because of the poor outcomes with conventional therapy.
  • Fifty-three cases were identified consisting of systemic anaplastic large cell (n = 18), PTCL unspecified (n = 17), angioimmunoblastic (n = 9), nasal type extranodal NK/T (n = 7), hepatosplenic (n = 2), and adult T cell leukemia/lymphoma (n = 1).
  • Fifteen patients were transplanted in first complete or partial response (CR1/PR1), 32 in second or beyond CR or PR (CR2/PR2+), and 11 with primary refractory disease (REF).
  • However, AHCT with conventional salvage chemotherapy has minimal durable benefit in patients with relapsed or refractory PTCL, and thus novel strategies and/or allogeneic HCT should be more aggressively explored in lieu of AHCT for relapsed/ refractory PTCL.